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ABSTRACT 
 
DEVELOPMENT OF A MODIFIED CALCIUM-BASED COMPOSITE CERAMIC 
BONE GRAFT MATERIAL 
 
 
 
By 
Gavin Andrew Buckholtz 
August 2015 
 
Dissertation supervised by Professor Ellen S. Gawalt 
 Composites consisting of both calcium aluminum oxide and hydroxyapatite were 
tested for their applicability as bone replacement scaffolds. Implanted bone scaffolds may 
fail due to a variety of reasons, including mechanical and biological failure. Mechanical 
failure may occur as a result of dissimilar properties between the surrounding healthy bone 
and the scaffold. Biological failure can occur due to integration problems at the interface 
of the scaffold and the natural bone, or as a result of implant associated infections as a 
result of bacterial attachment and biofilm formation. Calcium aluminum 
oxide:hydroxyapatite composites were developed that address these three modes of implant 
failure through physical modification of the composition of the materials and chemical 
modification of the interface of the material. 
 v 
 The composites were evaluated for phase composition, elastic modulus, modulus 
of rupture, degradability, osteoblast attachment, percent viability and proliferation. 
Characterization was completed using powder x-ray diffraction (PXRD), a four point 
bending test, scanning electron microscopy (SEM), scanning electron microscopy-energy 
dispersive x-ray spectroscopy (SEM-EDS), diffuse reflectance infrared Fourier transform 
(DRIFT) spectroscopy, fluorescence spectroscopy, direct infusion quadrupole-time of 
flight mass spectrometry (Q-TOF MS), Escherichia coli N-phenylnaphthylamine (NPN) 
uptake and bacterial turbidity tests, and Live/Dead® and alamarBlue® tissue culture 
assays. Composites with greater than 10% HA by mass were mechanically weak and ruled 
out as scaffolds. However, 1-5% HA composites were mechanically similar to non-load 
bearing bone and all resulted in increased osteoblast response at extended time points. The 
antimicrobial peptide Inverso-CysHHC10 was successfully linked to the 5% HA composite 
using an interfacial alkene-thiol click reaction. The linked AMP retained its effectiveness 
against Escherichia coli based on NPN uptake assays and bacterial turbidity tests. Most 
importantly, the immobilization of the antimicrobial peptide did not affect the increased 
osteoblast response observed on the unmodified 5% HA. The Inverso-CysHHC10 
modified composites present a new class of composite biomaterials that are able to 
simultaneously address issues with mechanical mismatching, osteoconductivity and 
implant site infection.  
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Chapter 1: Background 
1.1 Introduction 
 There are more than 3 million musculoskeletal procedures performed annually in 
the United States, with approximately half of those involving bone graft procedures.1 Bone 
grafts are frequently used to treat skeletal injuries including fractures, tissue degenerative 
diseases and bone resection, generally as a result of cancer.2-6 The autograft and the 
allograft are currently the two most common methods of bone replacement, comprising 
about 90% of the performed procedures.7 Only the remaining 10% of bone grafts utilize a 
synthetic graft source.7 Whatever the graft source may be, the material must be able to 
address the physiological stresses placed on it when it is used in an in vivo setting. The 
primary stresses placed on a graft material are mechanical and biological, and due to the 
nature of the autograft, it remains the most desirable source of boney tissue.8,9 However, 
the extent of skeletal injury can often limit the opportunity for an autograft to be used, 
based on the size and severity of the bone loss. But, with recent progress in biomaterials 
research, tissue engineering and mechanical engineering, there is hope that a synthetic bone 
graft material can be developed and tuned for its applicability.10-12 The ideal synthetic bone 
graft material would be mechanically similar to natural bone and biologically similar to the 
autograft. 
 
1.2 Bone Scaffold Requirements 
 The mechanical strength and biological activity of a bone graft material are both 
critical aspects in determining the applicability of a synthetic scaffold material used to fill 
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a critically-sized bone defect, anything larger than 4 mm in size.13-16  Synthetic graft 
materials must be mechanically similar to the natural bone that will surround them upon 
implantation, resistant to corrosion and degradation under physiological condition, non-
cytotoxic to healthy cells, able to stimulate increased cellular attachment, viability and 
proliferation and resistant to bacterial attachment and colonization.17-20  
 
1.2.1 Mechanical Requirements 
 The scaffold should have similar strength to the cortical or cancellous bone that it 
will be used to replace.9,21,22 This is important for a couple reasons. First, it is important 
because most scaffolds are designed to act as mechanical supports for the injury site, with 
the long term goal of healthy tissue eventually replacing the graft. Second, the location of 
the graft will dictate the mechanical properties necessary. Natural load bearing cortical 
bone, such as the femur, is much stronger than non-load bearing cancellous bone, such as 
the skull or jaw, and the mechanical properties of the scaffold should be similar to those of 
the natural surrounding bone.  
 
Table 1.1: Mechanical properties of natural bone and materials used in implant procedures. 
 
 
 
  
 
 
 
 Elastic Modulus (GPa) Modulus of Rupture (MPa) 
Load Bearing          
Cortical Bone23 
15-22 60-75 
Non-Load Bearing 
Cancellous Bone23 
3-11 4-9 
Ti-6Al-4V Alloy 
Biomaterial24 
100-115 800-1000 
Hydroxyapatite (Sintered)25 80-110 600-800 
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 Biomaterials that are too weak provide poor mechanical support and result in 
fracture or dislocation of the scaffold. But biomaterials that are stronger than the 
surrounding tissue result in the stress shielding of the surrounding natural bone by the 
biomaterials and can lead to bone resorption, weakening and fracture.26-28  
 Since bone scaffolds are designed to act as mechanical support while new, healthy 
bone regenerates the material should not rapidly degrade.29 If the scaffold degrades too 
rapidly, it does not give the healthy tissue an opportunity to integrate and vascularize, both 
critical steps in new bone formation. Also, too rapid of degradation can lead to implant 
loosening and failure. However, if the scaffold does not break down at a rate approximately 
equal to the rate of new bone regeneration it can result in the buildup of boney tissue at the 
scaffold-tissue interface and can also lead to implant rejection.  
 
1.2.2 Biological Requirements 
 The biological requirements of a biomaterial are the most important and can often 
be tuned to overcome minor mechanical differences. An ideal bone scaffold material 
should be osteoconductive, osteoinductive, osteogenic and osteointegrative.21,22,30 
Osteoconductivity is the ability of the scaffold to support attachment and growth of 
osteoblasts, cells necessary for new bone formation.21,22,30 Osteoinductivity is the ability of 
the scaffold to induce the differentiation of mesenchymal stem cells into osteoblasts.21,22,30 
The ability of a material to induce this differentiation is important in the formation of new 
bone cells and bone tissue. A scaffold that is osteogenic allows living cells to proliferate 
on and within the material, leading to the eventual replacement of graft material with 
natural tissue.21,22,30 Finally, osteointegration is the capability of the scaffold material to 
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bind with the natural bone. Improper osteointegration can lead to implant dislocation and 
graft failure.21,22,30 
 The physical properties of a scaffold material often play a role in the 
osteoconductivity and osteoinductivity.19 Primarily the porosity, including size and 
connectivity, of a material effect the osteoconductivity and osteoinductivity. Natural bone 
can be up to 90% porous which leads to the ability to vascularize the tissue and leads to 
healthy tissue formation.31-33 If a material is non-porous the cells tend to only grow on the 
surface and the graft may fail.34  
 However, the chemical composition of the scaffold has also been shown to effect 
the osteoconductivity and osteoinductivity. Where CaAlO based materials have 
demonstrated the necessity of chemical functionalization for the addition of these 
characteristics.35-37 Calcium phosphate materials, including β-tricalcium phosphate and 
hydroxyapatite, have shown increased material osteoconductivity and osteoinductivity 
through the simple addition of these phases to a variety of materials.37,38 By incorporating 
these phases, it has been shown that the physical shortcomings of a material can be 
overcome.  
 
1.3 Current Bone Replacement Materials 
1.3.1 Autografts and Allografts 
 The autograft and allograft are the only types of bone graft materials that are based 
on natural human tissue. The autograft is considered the gold standard of bone graft 
technology because it is the only material that supports osteoconductivity, osteoinductivity 
and osteointegration.9 The autograft is a piece of bone tissue harvested from the patient’s 
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own body.39,40 This graft is the most desirable because the tissue is from the patient and 
therefore the risk of immune response and disease transmission are minimized.41 However, 
the procedure to acquire the autograft presents significant concerns. Obtaining the autograft 
tissue requires a second surgical site and risks donor site infection, morbidity and possible 
chronic pain.41,42 The final drawback to the autograft is the limitation of tissue 
availability.43 The autograft has been successful in small applications, however a patient 
only has a finite amount of donatable tissue. If the skeletal injury is too severe, then despite 
the advantages of the autograft, an allograft is often used. 
 The allograft is a piece of boney tissue that is harvested from a donor, typically 
shortly following death.40 Upon removal the bones are cleaned of all soft tissue and 
sterilized using ethanol or gamma radiation.44,45 The sterilized bone can then be stored until 
it is needed for a surgical procedure. Allografts have the benefit of a larger size availability 
and they minimize the donor site complications associated with autografts.46 However, 
allografts have several significant risks associated with them. Due to post resection 
processing the tissue lacks osteoinductive properties and becomes mechanically 
weaker.21,47 Also despite the sterilization process disease transmission from donor to 
recipient has been observed.45,48,49 Finally, the biggest risk is long-term host rejection 
which requires drug therapy.50,51  
 
1.3.2 Metal Alloys and Metal Oxides 
 As mentioned, only about 10% of bone replacement procedures utilize a synthetic 
bone scaffold material. The majority of these are metal replacements utilized when the 
bone defect is critically-sized and the location of the injury is to load bearing bone. 
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Frequently stainless steel, titanium and cobalt-chromium alloys are utilized in these types 
of applications.52,53 Stainless steel alloys are useful as biomaterials because they are more 
ductile than other alloys and the surface can be physically adjusted for surface roughness, 
surface oxygen content and surface energy demonstrated that osteoblast cell adhesion, 
spreading and growth rate was increased for one-day adhesion tests on CO2 laser-treated 
samples.54 Also they showed that the mechanically roughened surface results in a slight 
enhancement in cell proliferation.54 Titanium based alloys are regularly used as total 
replacement materials because they have a high strength to weight ratio and tend to be the 
most bio-inert alloy.55 Titanium alloys, including Ti-6Al-4V, have shown increased 
osteoblast adhesion, differentiation and calcification when the alloy surface was rough.56 
Nano-patterned titanium substrates demonstrated improved osteoblast adhesion and 
morphology on linearly aligned features similar to the size and orientation of collagen and 
hydroxyapatite in long bones.57 Cobalt-chromium alloys are widely used due to high 
mechanical strength and hardness that limits wear over time.28 Co-Cr alloys modified with 
BMP-2 showed a two-fold increase in osteoblast differentiation after two weeks and a four-
fold increase in calcium deposition after three weeks.58 Both physical and chemical 
modification have demonstrated their ability to increase the biocompatibility of synthetic 
metal replacement devices. 
 
1.3.3 Ceramics 
 Due to their chemical stability and mechanical strength, calcium aluminum oxide 
cements have been evaluated for use a synthetic graft materials.59-61 CaAlO possesses a 
variety of desirable characteristics for bone grafting procedures. The material is easily 
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prepared using hydration, making it easy to fabricate necessary shapes and designs.35,36 In 
addition to the ease of fabrication, CaAlO has low degradability and cytotoxicity, under 
normal physiological conditions. CaAlO has also been shown to not lose its mechanical 
strength through autoclave sterilization and is readily functionalized with cell adhesion 
peptides and antibiotics using interfacial reactions.35,36  
 Due to the chemical similarity to natural bone, calcium phosphate ceramics have 
also been investigated.16,62,63 When cast as HA, the material has been shown to be 
osteoconductive and osteointegrative.38,63 The material can also be slowly resorbed through 
cell mediated resorption, allowing for replacement with natural tissue.64,65 Many available 
biomaterials utilize HA as part of their material, including the Vitoss Bone Graft Substitute. 
HA demonstrates increased osteoconductivity and osteoinductivity, but work has also 
shown that this material can be further functionalized with adsorbed antibiotics (including 
vancomycin, gentamicin and ciprofloxacin) and linked antibiotics (tetracycline) to make 
them even more attractive options as multifunctional synthetic bone graft materials.66-68 
 
1.3.4 Bioactive Glasses 
 Bioactive glasses are hard, non-porous materials typically composed of a 
combination of sodium oxide, calcium oxide, silicon dioxide and diphosphorus pentoxide 
that are being investigated for bone repair.21,69 These materials are safe to implant and can 
be engineered for specific purposes. First the sodium ions in the glass are replaced by 
protons, then hydrolysis of the silicon dioxide leads to the precipitation of a calcium 
phosphate on the material that mineralizes into HA.  
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 Ajita et al examined the effect of particle size on mesenchymal stem cell 
proliferation of bioactive glasses.70 They have shown that the smaller the bioactive glass 
nanoparticles the greater the amount of cell proliferation. Bi et al studied the effect of 
bioactive glass microstructure (trabecular, fibrous and oriented) on bone regeneration in a 
rat calvarial defect model.71 Twelve weeks after implantation the trabecular bioactive glass 
formed new bone over 33% of the initial defect, as opposed to 23% and 15% for fibrous 
and oriented. The new bone formed with trabecular bioactive glass also had a higher 
average blood vessel area.  
 
1.4 Failure of Graft Materials 
1.4.1 Mechanical Failure 
 Failure of bone grafts is most commonly the result of mechanical issues. Corrosion 
and degradation of the synthetic material in vivo often leads to decreased osteointegration 
at the tissue:bone graft interface.72,73 Often the result of this is loosening of the graft in the 
implant site and subsequent failure. Although metallic biomaterials tend to be made from 
metals that are thought to be corrosion resistant, crevice and stress corrosion can still occur 
in load bearing implants.74 
 Mechanical mismatching of the biomaterial to the surrounding natural tissue is 
frequently a cause of failure.75,76 If the mechanical properties of the graft are different than 
the tissue it is replacing then stress shielding, healthy bone resorption, implant loosening 
and implant fracture can occur (Figure 1.1a).26-28 Specifically a mismatch of the elastic 
modulus between natural bone (3-11 GPa for non-load bearing cancellous bone, 15-30 GPa 
for load bearing cortical bone) and metallic biomaterials (~100 GPa for Ti and ~200 GPa 
 9 
for CoCr). When a biomaterial is more stiff than the surrounding natural bone, it takes 
away the mechanical requirements of the natural bone.77 When the natural bone is exposed 
less mechanical stress, the bone begins to resorb, weakening the tissue:graft interface and 
resulting in graft failure.28  
 Ceramics and bioactive glasses are frequently used in non-load bearing applications 
because when they are used in load bearing applications they are unable to withstand the 
stresses placed on them, often ending in graft fracture.22,78 Bioactive glasses are quick to 
degrade and convert to hydroxyapatite, which is an issue if the healthy tissue is not growing 
back at a rate appropriate to its degradation. Ceramics, on the other hand, tend to degrade 
slowly, which leads to slow integration. If the material is subjected to a stress prior to 
integration, fracture and dislodging can occur.  
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Modes of artificial graft failure including a) healthy bone resorption due to 
mechanical mismatching, b) fibrous encapsulation due to non-specific protein adsorption 
and c) biofilm formation due to attachment of bacteria and polysaccharide matrix 
production. 
 
Bone 
Graft 
Bone 
Graft 
Graft 
Bone 
a) Healthy bone resorption 
b) Fibrous encapsulation 
c) Biofilm formation  
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1.4.2 Biological Failure 
 Biomaterials can also fail as a result of biological issues. The ideal graft would be 
osteoconductive, osteoinductive, osteogenic and osteointegrative, however current 
biomaterials are not able to address all four of these characteristic simultaneously, and can 
result in a variety of bone tissue-graft merger issues.21,22,30 Two methods of biological 
failure include fibrous tissue encapsulation and infection.18,22,79-81  
 In the case of fibrous encapsulation, the failure is the result of an immune response 
that leads to problems with implant integration and eventual implant rejection. Biomaterial 
implantation results in the non-specific adhesion of proteins and cells.77,82 The presence of 
blood at the surgical site leads to the production of fibrin and recruitment of white blood 
cells.18 Macrophages then settle on the implant and recruit fibroblasts that create a barrier 
between the tissue and the biomaterial (Figure 1.1b). Also, the adhesion of fibrinogen to 
the material, which can cross-link with other proteins, can result in fibrous 
encapsulation.77,83-85 If either of these two encapsulation events were to take place, the 
biological response of the host would lead to significant implant loosening and eventual 
failure.  
 Biological failure can also result from infection.82,86-88 Implant infection generally 
occurs at the time of implant surgery or early on in the wound healing process.89,90 Bacteria 
can adhere to the surface of the implant shortly before or immediately after surgery; since 
the non-specific adhesion of proteins can form a conditioning film on the material.91  Once 
the bacteria are attached they can begin to grow into bacterial colonies known as biofilms, 
where the bacteria are enclosed in a polysaccharide matrix that protects them from 
conventional antibiotic treatment (Figure 1.1c).82,89 Further the bacteria undergo a 
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phenotype change to sessile organisms which have reduced need for nutrients. While 
enclosed in the biofilm the bacteria can become more virulent, which becomes an issue 
when the biofilm releases planktonic cells or biofilm clusters that can spread to other areas 
of the body.92,93 Frequently the best approach to eradicate a biofilm infection is to remove 
the initial implant, treat the infection, then insert a new implant.81,89,90  
 
1.5 Current Literature Approaches to Materials Modification 
1.5.1 Metal Alloys and Metal Oxides 
 Metals possess the mechanical strength necessary for load bearing boney 
applications, but these materials tend to not be biodegradable, do not allow for cell 
ingrowth, lead to increased fibrous tissue formation and can lead to stress-shielding and 
healthy tissue weakening. As mentioned previously, different research strategies are being 
evaluated to help increase the biocompatibility of the materials. Physical modification, 
including etching and porous material fabrication, of stainless steels, titanium and cobalt-
chromium are being investigated to increase in vitro bone cell attachment and in vivo bone 
cell in growth. By introducing pores on the metal surfaces, in vivo performance is enhanced 
through increased vascularization, leading to increased nutrient supply, and increased new 
bone in growth and regeneration.  
 Chemical modification of the surfaces of metal replacement materials has been 
more widely performed as a means to improve biocompatibility of metal oxides. Stainless 
steel alloys have been chemically modified with antibiotics that operate synergistically to 
reduce bacterial colonization for up to 48 hours.94 The surface of the nitinol alloy has been 
modified to reduce its corrosion subsequently reducing the amount of metal ions that are 
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released into the body that can cause cytotoxic and genotoxic effects.95 Through the 
implementation of these types of interfacial modifications the surface properties of a 
variety of metals and alloys can be improved to increase their efficacy and applicability.  
 To overcome the issues associated with mechanical mismatching and failure 
associated with stress shielding there has been work examining biodegradable metal and 
alloys, including magnesium and iron.96 Using these mechanically strong, but degradable 
metals, provides the temporary mechanical support with the ability to degrade in a 
physiological environment while allowing for new bone regeneration.  
 
1.5.2 Composite Materials 
 Composite materials aim to combine the best attributes of one material with those 
of another material, to design a synthetic graft material with better function than any of the 
parts individually. Composites consisting of hydroxyapatite and other bioactive ceramic 
coatings on metals have shown promise by providing the bioactive properties of the coating 
with the enhanced mechanical properties of the metal beneath the coating.  
 Chen and coworkers created a composite consisting of a titanium core with a 
calcium coating. Their material was shown to induce apatite formation on the surface of 
the material when submerged in simulated body fluid.97 Gu et al produced a composite 
material that consisted of Ti-6Al-4V plasma-sprayed with HA. They also demonstrated the 
formation of a carbonate-apatite layer after a 2 week soaking in simulated body fluid.98  
 Composites of HA and collagen fibers have also been investigated. Natural bone is 
approximately 60% HA and 40% collagen by dry mass, so a composite of these materials 
may closely mimic natural bone. Du et al and Wu et al both demonstrated that a collagen 
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and HA composite produced mineralized bone in 21 days.99 Rovira and coworkers showed 
that an HA-collagen-elastin composite produced mineralized bone in 15 days.99  
  
1.5.3 Biomolecule Functionalization 
 Another approach to improving current biomaterials is interfacial modification with 
an assortment of active biomolecules. Molecules of interest include antibiotics to limit 
bacterial attachment and infection, cell adhesion peptides to promote specific cell adhesion 
improving osteoconductivity, and other proteins that have been shown to induce bone 
formation and vascularization. Although these modifications utilize different types of 
biomolecules, they all aim to improve the surface characteristics of the biomaterials and 
reduce the chance for implant failure. 
 The localized delivery of peptides and proteins on the biomaterial would be an 
advantageous approach to increasing biocompatibility and the osteoconductive properties 
of the material. Previous work has shown that modifying biomaterials with osteoblast 
adhesion peptides and bone morphogenetic proteins results in better bone cell performance 
and new bone formation.58,100 Several binding domains from the extracellular matrix 
peptides and proteins have been revealed and incorporated into short peptides. The most 
widely used is the arginine-glycine-aspartic acid (RGD) sequence.16,100 Cook et al first 
showed enhanced cell spreading on RGD modified poly(lactic acid-co-lysine) polymers.101 
Since that time, RGD modified materials have been used to increase fibroblast adhesion 
and spreading, endothelial cell attachment and osteoblast attachment on orthopaedic 
materials.36,102,103 Another example is the FDA approved InFUSE® Bone Graft that is used 
in primarily in spinal surgery. This device is a composite synthetic graft that is a titanium 
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cage with collagen located on the interior. The collagen is used to deliver recombinant 
human bone morphogenetic protein-2 (BMP-2). This protein has been shown to induce 
new bone growth by attracting osteoblast cells to the delivery site of the BMP-2.104  
 The delivery of active antimicrobials is also a critical part of implant success. 
Research has been conducted on antimicrobial surfaces that are (1) non-fouling (surfaces 
that avoid protein adsorption and cell adhesion) (2) colonized with non-pathogenic bacteria 
(occupy the surface to prevent attachment of pathogenic bacteria) (3) modified with 
biocidal substances (non-antibiotic molecules that have shown activity, including silver, 
quaternary ammonium compounds and nitric oxide) and (4) modified with antibiotics 
(vancomycin, tobramycin, ampicillin, gentamicin, etc.).105  Zhao et al and Subramani et al 
have successfully immobilized vancomycin to titanium and it was proven to be bactericidal 
to Staphylococcus aureus (S. aureus) and Staphylococcus epidermidis (S. 
epidermidis).106,107 Palchesko et al linked vancomycin to CaAlO and demonstrated its 
efficacy against S. aureus.35,108 However the utility of antibiotic coatings is dependent upon 
the activity of the linked antibiotic and the growing concern over the risk of development 
of antibiotic resistance in bacteria.  
 For these reasons, the focus has shifted for some to using antimicrobial peptides 
(AMP). These antimicrobials have broad spectrum efficacy, minimize the development of 
bacterial resistance and maintain effectiveness, even through sterilization.109-111 Glinel et 
al, Haynie et al, Humblot et al and Bagheri et al have all linked the AMP magainin I to a 
variety of materials through a variety of approaches.105 Despite different approaches the 
AMP was shown to be active against bacteria including, E. coli, S. aureus, Pseudomonas 
aeruginosa (P. aeruginosa) and Listeria ivanovii.105 Wilcox et al and Chen et al have linked 
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melimine to contact lenses and glass cover slips and shown its activity against S. aureus 
and P. aeruginosa.105 Finally, Gabriel and coworkers immobilized cathelin LL37 to 
silanized titanium surfaces and demonstrated activity against E. coli.105  
  
1.6 Summary 
 Although the autograft remains the optimal bone graft material due to its osteogenic 
properties, the growing concerns over the source of autologous bone and the risk of 
infection is driving the need to develop a better synthetic material.  Currently, most 
synthetic materials, including metals, alloys, ceramics, bioactive glasses and composite 
materials, are not able to address all of the mechanical and biological stresses that will be 
places on them in an in vivo setting. Although significant progress has been made through 
the creation of composite materials and the tuning of interfacial properties through organic 
functionalization with biomolecules, these synthetic materials still underachieve when 
compared to the autograft. Therefore, continuing research on the development of synthetic 
materials is necessary before the use of the autograft can be phased out and eliminated. 
 
1.7 Research Approach 
 Artificial bone graft materials must meet several requirements. They should be 
osteoconductive, osteoinductive, osteogenic and osteointegrative, all while being 
mechanically similar to the surrounding natural tissue and being resistant to bacterial 
attachment and colonization. Conferring all of these attributes into a single material has 
been a formidable task thus far.  
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 This project aimed to modify the composition of the previously, physically 
optimized CaAlO ceramic to enhance osteoblast response and to further develop the 
antimicrobial functionalization of the composite material. A composite CaAlO material 
was formed that included the osteoconductive and osteoinductive HA. As has been shown 
in previous literature, the goal was to increase the osteoconductivity and osteoinductivity 
of the CaAlO through this incorporation. Composites containing different percentages of 
HA were cast and evaluated to find the percentages that were mechanically similar to 
natural non-load bearing bone, and resulted in the greatest increase in osteoblast attachment 
and proliferation.  
 Further, the previously designed CaAlO material required a five-step reaction 
sequence to immobilize active antibiotic, vancomycin. In this project, the highly efficient, 
single step alkene-thiol click reaction was used to link the antimicrobial peptide Inverso-
CysHHC10. This linkage presents an improvement over the previous approach in multiple 
regards. First, the linkage approach is shorter, more efficient and introduces the synthetic 
material to less chemicals, as alkene-thiol click reactions can be performed without 
initiators. Secondly, the linking of an antimicrobial peptide is advantageous over antibiotics 
because antimicrobial peptides have broad spectrum efficacy, their mode of action does 
not rely on bacteria growth and division and the risk of development of bacterial resistance 
to antimicrobial peptides is limited.  
 This work evaluated the mechanical similarity of the developed composites to non-
load bearing cancellous bone, examined the increased osteoconductivity of the composite 
materials and determined the loading, stability and efficacy of the linked Inverso-
CysHHC10 antimicrobial peptide. 
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2 Chapter 2: Physical Characterization of Composite CaAlO:HA 
2.1 Introduction 
 Calcium aluminum oxide materials were previously utilized as bone graft materials 
and showed some promise in initial work, but they had since been discounted because of 
concerns over biocompatibility.1-6 However, in vivo work has shown that the calcium 
aluminum oxide materials do not illicit an inflammatory response demonstrating the 
biotolerability of the CaAlO material.7-11 More recent work has further demonstrated that 
through covalent chemical modification of CaAlO the biocompatibility of these materials 
can be increased and biological applicability can be tuned.7,12-14 However, other work has 
demonstrated that a different class of calcium ceramics, calcium phosphates, are 
biocompatible and are intriguing options for synthetic bone graft materials.8,15-17 
Composites of CaAlO and calcium phosphates, namely hydroxyapatite, were examined in 
this project because the materials are mechanically strong and through the introduction of 
the biocompatible HA, the biocompatibility of the CaAlO based material may be increased. 
 CaAlO casts are formed through a three-step mechanism.18,19 First the surface of 
the CaAlO aggregates are hydroxylated and they begin to dissolve until the saturation limit 
has been reached (dissolution).18,19 After dissolution the nuclei continue to grow in critical 
size and quantity, known as the nucleation phase.18,19 Finally, the precipitation phase occurs 
where the hydrates precipitate out of the solution.18,19 This process continues until all of 
the dissolved CaAlO has been precipitated. During the hydration process the phases bind 
together and interlock with one another, increasing the mechanical strength and forming 
the cast CaAlO. 
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  In a previous study, a variety of different ratios of CaAlO aggregates within casts 
was examined to physically optimize the material.14 The outcome was a ratio that produced 
CaAlO materials that were optimized for porosity, strength and degradability.14 Despite the 
optimization of the physical properties of the CaAlO material, the study revealed that the 
material was not optimized for its biological performance, and required total interfacial 
modification for biological activity.14 
 HA is formed through the hydration of calcium phosphate with phosphoric acid 
(Scheme 2.1). In the first step of the formation of HA, the Ca3(PO4)2 reacts with protons in 
solution to from the HA precursor brushite, CaHPO4.
20 The brushite molecules then react 
with water molecules and generate the solid HA phase.20 The formed solid HA molecules 
are not interlocked like those in the CaAlO material, therefore the HA is mechanically 
weak. To add mechanical strength to the HA, it can be sintered which fuses the powder 
together by heating and compacting without reaching the melting point of the       
material.21-24  
 
 
Scheme 2.1: Proposed reactions for the synthesis of hydroxyapatite from calcium 
phosphate tribasic. 
 
 Many prior studies have examined HA materials for their applicability as synthetic 
bone graft materials.8,25-27 These studies consistently demonstrate that biomaterials 
intended for boney applications often have increased biological activity when HA is 
present in the material.8,27  
Ca3(PO4)2 + 2 H
+                 2 CaHPO4 + Ca
2+ 
5 CaHPO4 + H2O                Ca5(PO4)3(OH) + 2 H3PO4 
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 In casting a composite of CaAlO and HA, the mechanical integrity of the material 
must be evaluated because CaAlO derives strength from through the hydration process and 
HA derives strength from sintering after hydration.18-20 If the post hydration treatment 
effects the mechanical integrity of the composite, then it must be determined which 
procedure is more appropriate for casting materials relevant to natural bone. By using the 
previously established methods for casting CaAlO and HA, to create a method to cast 
composite CaAlO:HA, the physical attributes of the new CaAlO:HA material can be 
physically characterized. 
 
2.2 Materials and Methods 
2.2.1 Materials 
 Calcium aluminum oxide (CaAlO) was supplied by Westmoreland Advanced 
Materials. Calcium phosphate tribasic (Ca3(PO4)2) and phosphate buffered saline (PBS, 
MgCl2 and CaCl2 free) were purchased from Sigma-Aldrich. Phosphoric acid (H3PO4) was 
purchased from Fisher Scientific (Certified ACS). All materials and chemicals were used 
as received unless otherwise noted. 
 
2.2.2 Casting Calcium-Based Ceramics 
2.2.2.1 Calcium Aluminum Oxide 
 Calcium aluminum oxide discs were prepared using a room temperature casting 
(20°C) of different sized aggregates of CaAlO containing the two phases, CaAl2O4 and 
CaAl4O7. The aggregate sizes utilized were -30+60, -60 and -200, in a 1:1:2 ratio, that are 
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previously separated using a sifting process that sorts out the particles based on their mesh 
size (Figure 2.1).13,14 The appropriate mass of each CaAlO aggregate size were thoroughly 
dry mixed at room temperature to ensure even particle distribution. Distilled deionized 
water (ddH2O) was then added to the aggregate powders at an amount equal to 0.3 mL of 
ddH2O per gram of CaAlO. The paste was allowed to thicken at room temperature for 10 
minutes. Afterwards, the CaAlO was poured into either: 1) a 6x2 mm (diameter x height) 
cylindrical disc mold or a 2) 17.75x2.5x1.67 cm (length x width x height) rectangular prism 
mold, where it was allowed to set for four hours. The CaAlO casts were rehydrated in their 
molds with ddH2O, and allowed to set overnight. The next day the casts were hydrated in 
their molds using ddH2O, then allowed to set for the night. The following day casts were 
removed from their molds and immersed into ddH2O for 24 hours to ensure hydration of 
the material. 
 
Figure 2.1: Casting 100% CaAlO in a 2:1:1 ratio of three different aggregate sizes. 
Through hydration the aggregates can be cast into a variety of shapes. 
 
2.2.2.2 Hydroxyapatite 
 Hydroxyapatite discs were also prepared using a room temperature cast 
approach.28,29 Fine particles of calcium phosphate tribasic were first obtained by grinding 
the Ca3(PO4)2 powder in a mortar and pestle for 10 minutes. Once the powder was ground, 
it was hydrated using a dilute phosphoric acid (H3PO4, 25 mM) solution at an amount equal 
CaAlO aggregate 
packing and binding 
within cast material 
+ + 
-30+60 -60 -200 
ddH2O 
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to 1.1 mL of H3PO4 per gram of Ca3(PO4)2 (Figure 2.2). Again the paste was allowed to 
thicken at room temperature for 10 minutes. After thickening the Ca3(PO4)2 was poured in 
the same molds as above, where it was allowed to set for four hours. After four hours the 
material was rehydrated in the molds using H3PO4, then allowed to set overnight. The 
following day the casts were rehydrated with H3PO4 in the molds and set for another night. 
The next day the casts were removed from their molds, rehydrated with H3PO4 for 24 hours 
and then were sintered for four hours at 1000°C using a programmable Lindberg/Blue 
Moldatherm Box Furnace (Model: BF51866A). The furnace was programmed to heat up 
from room temperature to 1000°C over a span of two hours, then remain at 1000°C for four 
hours, followed by a two hour cool down from 1000°C to room temperature. 
 
 
 
 
 
 
Figure 2.2: Casting 100% HA using ground Ca3(PO4)2 with 25 mM H3PO4. After casting 
the materials are sintered for strength. 
 
2.2.2.3 Calcium Aluminum Oxide:Hydroxyapatite Composites 
 Calcium aluminum oxide:hydroxyapatite (HA) composite discs (1-5, 10, 15, 20 and 
25%, by mass) were cast using a room temperature method that combined both the CaAlO 
and the HA methods. First the three different aggregate sizes of CaAlO (-30+60, -60 and -
200) were dry mixed in a 1:1:2 ratio. Upon thorough mixing, ground Ca3(PO4)2 was added 
to the mixed CaAlO powder at a mass appropriate for the desired composite composition 
(1-5, 10, 15, 20 or 25% HA, by mass). The powders were again thoroughly dry mixed to 
distribute the particles and then were hydrated with 0.3 mL of ddH2O per gram CaAlO and 
Sintered HA Ca3(PO4)2 Cast HA 
H3PO4 1000°C 
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1.1 mL H3PO4 per gram Ca3(PO4)2 in the composite. For example, 15 grams of a composite 
that is 95% CaAlO and 5% HA (known as 5% HA), required 7.125 grams of -200 mesh 
CaAlO, 3.563 grams each of the -60 and -30+60 mesh CaAlO, and 0.75 grams of 
Ca3(PO4)2. Upon mixing, 4.28 mL of ddH2O and 0.83 mL of H3PO4 was used to hydrate 
the powder. The paste was allowed to thicken for 10 minutes. Afterwards the paste was 
poured into the same molds mentioned above, where it was allowed to set for four hours, 
then was rehydrated using H3PO4 and allowed to set overnight. Composites were hydrated 
again the next day with H3PO4 and permitted to set overnight. The following day 
composites were removed from their casts and were rehydrated in ddH2O for 24 hours. 
 Once hydrated, half of the composite discs/beams were allowed to dry at room 
temperature (simulating exclusive CaAlO casting) and half were subjected to a four hour 
sintering at 1000°C (simulating exclusive HA casting). The two post hydration processes 
were examined because CaAlO derives much of its mechanical strength through using 
ddH2O to create chemical bonds between the aggregate powders during hydration, whereas 
mechanical integrity of HA is the result of sintering, the high temperature compaction and 
fusion of powders into solids. 
 
2.2.3 Powder X-ray Diffraction  
 Phases present in the cast composites were determined using powder x-ray 
diffraction (PXRD).14,30,31 Six discs of each material (100% CaAlO, 100% HA and 1-5, 10, 
15, 20 and 25% HA) were ground with a mortar and pestle for 20 minutes. Samples were 
then loaded onto an X’Pert PANalytical Pro and scanned from 5-70° 2Θ with a time per 
step of 720.090 seconds and a scan speed of 0.002947° per second. Collected diffraction 
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patterns were analyzed using X’Pert High Score Plus to match peaks in the collected 
sample patterns to reference database patterns. Peak overlap between the sample and 
reference patterns indicated a matched phase. 
 
2.2.4 Mechanical Evaluation  
 Eight total beams of each composite (0-5, 10, 15, 20 and 25% HA) were cast. Four 
composite beams were sintered at 1000°C for four hours and the other four were dried at 
room temperature. All composite beams were evaluated independently by mounting in an 
MTS 858 Bionix test machine in a fully articulated four point bending fixture (Figure 2.3). 
The middle supports were placed at 25% and 75% of the distance from the left, and a light, 
hollow, square brass structural beam of 6x6 mm with 0.4 mm walls was attached to the 
midpoint of the lower side of the beam, perpendicular to the axis of symmetry. Each side 
of the beam was in contact with a linear variable differential transformer. A tare load of 70 
N was applied to the beam and the deflection at the midpoint was recorded. Beams were 
then loaded at a speed of 0.5mm/s until failure, and the load and deflection were recorded. 
The average elastic modulus and the average modulus of rupture of each composite was 
then calculated and compared to the value for non-load bearing cancellous bone.  
 
 
 
 
 
Figure 2.3: CaAlO:HA composite beam loaded in the four point bending apparatus, prior 
to load application. 
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 The elastic modulus and modulus of rupture were calculated according to equations 
1 and 2, respectively. Where “l” is the distance between the two outer most loading points, 
“Fmax” is the maximum applied load, “b” is the specimen width, “h” is the specimen 
thickness, “ΔF” is the load range between a maximum 350 N load and the 70 N tare load 
and “f” is the difference in the midpoint beam deflections at 350 N load and the 70 N tare 
load. 
𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟏.  Elastic Modulus =  
11 ∙ ∆F ∙ l3
64 ∙ f ∙ b ∙ h3
 
𝐄𝐪𝐮𝐭𝐚𝐢𝐨𝐧 𝟐.  Modulus of Rupture =  
3 ∙ Fmax ∙ l
4 ∙ b ∙ h2
 
 
2.2.5 Scanning Electron Microscopy 
 Morphological characteristics of the cast composite materials (0-5% HA) were 
examined using scanning electron microscopy (SEM). Characteristics including composite 
topography and interfacial porosity were examined. Micrographs were collected between 
250-1400x magnification using a 2.00-7.00 kV accelerating voltage, dependent upon the 
surface feature and material being examined. Substrates were analyzed on a Hitachi S-
3400N-II SEM under full vacuum. 
 
2.2.6 Scanning Electron Microscopy-Energy Dispersive X-Ray 
Spectroscopy 
 Interfacial composition and interfacial phase distribution of the cast composite 
materials (0-5% HA) were examined using scanning electron microscopy-energy 
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dispersive x-ray spectroscopy (SEM-EDS) and elemental mapping. EDS spectra were 
collected on areas of the substrates that were large and flat, allowing for data collection 
over an area instead of a single point. Spectra were collected for two minutes from 0-20 
eV. Maps of all elements detected using EDS were also obtained. Elemental maps were 
collected on the same region of the substrate as the EDS spectra was collected. Maps for 
all elements were simultaneously collected for the duration of four minutes. All substrates 
were analyzed and spectra/maps collected on a Hitachi S-3400N-II SEM under vacuum 
using a Bruker XFlash with ESPIRIT software, under a magnification of 1400x and 
accelerating voltage of 15.0 kV.  
 
2.2.7 Degradability Study 
 The long term stability of the composite material in an aqueous environment was 
evaluated through immersion in phosphate buffered saline (PBS) for three months at 37°C 
and 5% CO2. Ten discs each of 0-5% HA were cast and weighed for their initial mass, 
recorded as week 0 (n=10). Discs were then added to individual wells of a 48 well plate, 
immersed in 1 mL of PBS and placed into an incubator at 37°C and 5% CO2. Well plates 
were removed from the incubator weekly, and the discs were transferred from the well 
plate into test tubes and then were heated at 120°C for 4.5 hours to ensure the removal of 
the liquid. Each disc was individually massed at the weekly time point. The discs were then 
placed into individual wells of a new 48 well plates, immersed in 1 mL of fresh PBS and 
they were returned to the incubator for another week. This process was carried out weekly 
for the duration of three months and the average change in mass between weeks was 
determined for each composite.  
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2.2.8 Statistics 
 A one-way analysis of variance (ANOVA) with a Bonferroni post-hoc test was used 
to determine the averages and examine statistical differences between the elastic moduli 
and moduli of rupture of the cast composites (0-5, 10, 15, 20 and 25% HA) and between 
the sintered and RT-formed composites. Additionally, the average weekly change in mass 
of all of the composites was compared. Both were evaluated at the p<0.05 level of 
significance and all data is reported as mean ± standard error.  
 
2.3 Results 
2.3.1 Powder X-Ray Diffraction  
 To determine the phases present in the composite materials, PXRD was utilized. 
The phases of the CaAlO starting aggregates are CaAl4O7 and CaAl2O4. Phases present in 
the room temperature cast 100% CaAlO include CaAl4O7, CaAl2O4, and a new hydrated 
calcium aluminum phase, Ca3Al2(OH)12.
14 In the composite materials (1-5, 10, 15, 20 and 
25% HA) Ca3(PO4)2, was added in as the source of HA. PXRD analysis of the RT-formed 
composites revealed the same three phases of CaAlO, as well as Ca5(PO4)3(OH), which is 
HA, and trace amounts of the HA precursor, CaHPO4·2H2O (Figure 2.4).  
 The presence of the same phases in both the RT-formed composites and the 
exclusively cast CaAlO and Ca3(PO4)2 demonstrates that the phases are not mixing and no 
cross reactions are taking place when the composites are cast. Thus the osteogenic benefits 
of the HA phase may be preserved through the RT casting. 
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Figure 2.4: A) PXRD pattern for the 5% HA composite and phases contained within the 
composite. Including the calcium aluminum oxide based phases B) CaAl4O7, C) CaAl2O4 
and D) Ca3Al2(OH)12 and the calcium phosphate based phases E) Ca5(PO4)3(OH) and          
F) CaHPO4·2H2O. 
  
2.3.2 Mechanical Evaluation 
 Different post hydration procedures were examined because CaAlO derives its 
mechanical strength from hydration, whereas the mechanical integrity of HA is the result 
of sintering. Composites ranging from 0-5, 10, 15, 20 and 25% HA were cast into two 
groups (sintered: heated at 1000°C for 4 hours and RT-formed: dried at room temperature) 
and evaluated for their elastic modulus and modulus of rupture.32,33 When examining bone 
for these properties, the value depends largely on the bone type, location and purpose.32,34 
Cortical bone is the dense, rigid bone tissue that is found largely in load bearing locations, 
whereas cancellous bone is the porous, more flexible bone tissue found primarily in non-
load bearing locations.32 Both the elastic modulus and modulus of rupture of cortical bone 
have been shown to be higher than those of cancellous bone.32 However, mechanically 
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matching a composite CaAlO to either of these types of bone would be useful for guiding 
the materials applicability. 
 
2.3.2.1 Elastic Modulus 
 The elastic modulus of a material is a measure of the resistance to non-permanent 
deformation when an external force is applied. Beams composed of 100% CaAlO cast at 
room temperature were found to have an average elastic modulus of 14.5 ± 0.9 GPa. As 
HA was incorporated into the mixture it was found that the elastic modulus of the 
CaAlO:HA composites tended to decrease as the mass percent of HA increased. 
Specifically, the 1%, 3% and 4% HA composites were statistically equivalent to control 
100% CaAlO, the 2% HA composite was statistically higher (16.2 ± 0.5 GPa) than control 
and the 5, 10, 15, 20 and 25% HA composites had a statistically lower elastic moduli than 
control (Figure 2.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Average elastic modulus of the composites of sintered and RT-formed 0-5, 10, 
15, 20 and 25% HA composites, shown as mean ± standard error, p<0.05. RT-formed 
composites are statistically higher for all percentages evaluated. 
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Table 2.1: Elastic modulus of the sintered and RT-formed CaAlO:HA composites. 
 
 
 
 
 
 
 
 
 
 
 
 In spite of the statistical differences amongst the composites, the elastic moduli for 
the 5, 10, 15, 20 and 25% HA RT-formed composites were all within the reported range 
for non-load bearing, structural cancellous bone, between 3-11 GPa (Table 2.1).32,35 All of 
the composites, 1-5, 10, 15, 20 and 25% HA, had elastic moduli lower than that reported 
for cortical bone.  
 The RT-formed beams were also compared to their sintered counterparts. The 
results demonstrate that sintering the composites at 1000°C for 4 hours significantly 
decreases the elastic modulus of the material for all of the composites examined. The 5% 
HA composite had the smallest average difference (70% decrease) between sintered and 
RT-formed materials and the maximum difference found was for the 1% HA composite 
(90% decrease). 
Material Sintered/RT-formed Elastic Modulus (GPa) 
0% HA RT-formed 14.5 ± 0.9 
1% HA Sintered 1.8 ± 0.3 
 RT-formed 15.9 ± 0.9 
2% HA Sintered 3.1 ± 0.3 
 RT-formed 16.2 ± 0.5 
3% HA Sintered 2.5 ± 0.4 
 RT-formed 13.8 ± 1.4 
4% HA Sintered 2.7 ± 0.2 
 RT-formed 13.9 ± 1.1 
5% HA Sintered 2.6 ± 0.3 
 RT-formed 9.9 ± 1.1 
10% HA Sintered 1.4 ± 0.1 
 RT-formed 5.2 ± 0.4 
15% HA Sintered 0.9 ± 0.1 
 RT-formed 3.7 ± 0.6 
20% HA Sintered 0.2 ± 0.02 
 RT-formed 3.2 ± 0.7 
25% HA Sintered 0.7 ± 0.1 
 RT-formed 2.6 ± 0.5 
 40 
2.3.2.2 Modulus of Rupture 
 The modulus of rupture of a material is a measure of the ultimate force necessary 
to cause failure. Composites that were 100% CaAlO cast at room temperature were found 
to have an average modulus of rupture of 8.8 ± 0.9 MPa. As HA was incorporated into the 
mixture it was found that at low percentages the modulus of rupture was not significantly 
affected and at high percentages the modulus of rupture decreased. Specifically, the RT-
formed 1% and 3-5% HA composites were statistically equal to control 100% CaAlO, the 
2% HA composites were statistically higher (10.8 ± 0.6 MPa) than control CaAlO and the 
10, 15, 20 and 25% HA composites were lower than control (Figure 2.6).  
 
 
 
 
 
 
Figure 2.6: Average modulus of rupture of the composites of sintered and RT-formed 0-
5, 10, 15, 20 and 25% HA composites, shown as mean ± standard error, p<0.05. RT-formed 
composites are statistically higher for 1-5% HA and statistically equal at greater 
percentages of HA.  
 
 Despite statistical differences among the composites, the moduli of rupture for the 
RT-formed 1, and 3-5% HA composites were all within the reported range for non-load 
bearing, structural cancellous bone, between 4-9 MPa (Table 2.2).32,35 The modulus of 
rupture of all of the composites were significantly lower than cortical bone. 
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Table 2.2: Modulus of rupture of the sintered and RT-formed CaAlO:HA composites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  RT-formed beams were again compared to their sintered counterparts, 
revealing that sintering the 1-5% HA composites caused a significant decrease in the 
modulus of rupture, but at higher percentages of HA sintering did not significantly affect 
the modulus of rupture. The smallest percent difference in average strength between 
sintered and RT-formed materials was found for the higher percentage composite 10%, 
15% and 25% HA composite (10-20% decrease) and the largest difference was for the 1% 
HA composite (70% decrease). 
 
2.3.3 Scanning Electron Microscopy 
 After using the mechanical evaluation to focus the study on mechanically-relevant 
composites, the 0-5% HA composites were qualitatively evaluated using SEM to determine 
Material Sintered/RT-formed Moduli of Rupture (MPa) 
0% HA RT-formed 8.8 ± 0.9 
1% HA Sintered 2.9 ± 0.6 
 RT-formed 10.1 ± 0.6 
2% HA Sintered 5.0 ± 0.4 
 RT-formed 10.8 ± 0.6 
3% HA Sintered 4.1 ± 0.3 
 RT-formed 9.7 ± 0.4 
4% HA Sintered 4.5 ± 0.2 
 RT-formed 9.1 ± 0.4 
5% HA Sintered 3.9 ± 0.1 
 RT-formed 6.4 ± 0.7 
10% HA Sintered 3.0 ± 0.3 
 RT-formed 2.8 ± 0.2 
15% HA Sintered 1.6 ± 0.3 
 RT-formed 2.0 ± 0.1 
20% HA Sintered 0.4 ± 0.03 
 RT-formed 1.6 ± 0.1 
25% HA Sintered 1.1 ± 0.2 
 RT-formed 1.4 ± 0.1 
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material morphology. It was found that the 100% CaAlO material adopted a topography 
that was rough and non-uniform, containing surface structures that were needle-like, plate-
like and cubic (Figure 2.7 A-C). As small mass percentages of HA were added into the 
CaAlO, the topography of the composites became more uniform and the distinct surface 
structures observed in 100% CaAlO were no longer present. The interface of the 
composites appear smoother, like that of cast 100% HA (Figure 2.7 D-E). 
 
Figure 2.7: Morphological SEM images of surface structures observed on CaAlO, 5% HA 
and HA. A) Needle-like formation of CaAlO. B) Plate-like formation of CaAlO. C) Cube-
like formation of CaAlO. D) Increased surface uniformity observed on 5% HA, similar to 
interfacial characteristics of HA. E) Interfacial structure of 100% HA. 
 
 
 
2.3.4 Energy Dispersive X-Ray Spectroscopy 
 The interfacial composition of the 0-5% HA composites was evaluated using SEM-
EDS and elemental mapping to determine the elemental and phase composition. Interfacial 
analysis confirmed the presence of the elements calcium, aluminum and oxygen in all 0-
5% HA composites examined, as a result of the CaAl4O7, CaAl2O4 and Ca3Al2(OH)12 in 
cast CaAlO (determined using PXRD). As Ca3(PO4)2 was incorporated into the material, it 
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cast as the phase HA, Ca5(PO4)3(OH) (determined using PXRD), and was present at the 
composite interface, determined by the presence of the EDS peak corresponding to 
phosphorus at 2.0 eV and elemental mapping of phosphorus. Additionally, the intensity of 
the EDS peak corresponding to phosphorus increased as the composite increased from 1% 
to 5% HA, indicating that as the mass percentage of HA in the composite increased, the 
amount of HA present at the interface also increased. A greater interfacial amount of HA 
is significant because it can lead to increased exposure and interaction between osteoblasts 
and the osteogenic phase of the composite. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: EDS spectra for 0, 1, 3 and 5% HA exhibit the presence of calcium, aluminum, 
and oxygen from the CaAlO phases. The 1, 3 and 5% HA composites contain phosphorus 
due to the HA and brushite phases. Elemental mapping shows the distribution of the HA 
phase at the composite interface based on the location of the phosphorus atoms and the 
aluminum atoms show that the majority of the interface is CaAlO. 
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2.3.5 Degradability Study 
 The long term stability of the 1-5% HA composites and control CaAlO was 
evaluated by immersion in PBS for 3 months. Substrates were placed into individual wells 
of a 48 well plate, immersed in 1 mL of fresh PBS and put into an incubator at 37°C and 
5% CO2. Substrates were removed from the incubator weekly and PBS was driven off then 
substrates were weighed. 
  Overall, the 1-5% HA composites exhibited a similar trend in their average week-
to-week change in mass when compared to one another. However, between Week 0 and 1 
the composites (1-5% HA) experienced a statistically significant drop in mass compared 
to the control CaAlO. For example, the average decrease in mass of control during Week 
1 was 0.23 ± 0.34 milligrams and for 5% HA it was 1.94 ± 0.35 milligrams. This decrease 
in mass can be attributed to the dissolution of solid CaAlO and/or Ca3(PO4)2 that remains 
in the composites after the casting process, because these phases are soluble in water. 
However, the observed decrease in mass during the first week was not statistically different 
among the 1-5% HA composites (Figure 2.9). 
 Between Weeks 1 and 2 the mass of control CaAlO and 1%, 2%, and 5% HA all 
increased by statistically the same mass, and 3% HA and 4% HA increased by a 
significantly greater amount than the others. Specifically, in Week 2 the control increased 
by 2.22 ± 0.30 milligrams and the 5% HA by 2.20 ± 0.28 milligrams, whereas the 3% HA 
increased by 3.01 ± 0.18 milligrams. Despite the differences in the mass changes in the 
early weeks of the assay, the mass change of all samples (0-5% HA) converged to zero 
grams when the degradability assay was extended through 3 months, indicating that the 
material was not degrading and remained stable in the PBS (Figure 2.9). 
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Figure 2.9: Average change in mass from week to week for 0-5% HA composites over a 
3 month time span. 
 
2.4 Discussion 
 The 100% CaAlO had previously been physically characterized for interfacial pore 
size and volume, phase presence, degradability and fibroblast attachment.14 It was 
determined that the 2:1:1 ratio of -200, -30+60 and -60 CaAlO aggregate sizes resulted in 
the material that was physically the most applicable, with pores of 100 μm diameter, no 
free Al3+ ions, long term stability in PBS and increased fibroblast (scar tissue cells) 
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adhesion at short time points.14 In spite of the fact that the material was physically 
optimized and increased fibroblast adhesion, it required chemical optimization to allow for 
bone cell attachment.12,14 This chemical modification was important because it introduced 
a five-step reaction sequence that culminated in the linkage of KRSR, an osteoblast 
adhesion peptide, and vancomycin, an antibiotic active against gram-positive strains of 
bacteria.12,13 Through the introduction of the osteogenic HA into the materials, the goal 
was to maintain the material’s mechanical strength while increasing osteoblast response, 
and decreasing the extent of chemical modification necessary to develop a multifunctional 
bone graft material.  
 Ca3(PO4)2 was added to the CaAlO powder as the source of HA for the composite 
material. When the composite materials are cast, PXRD demonstrated that the Ca3(PO4)2 
does cast into HA. However, to analyze the composites using PXRD the discs had to be 
ground into a fine powder following the casting, therefore PXRD demonstrated the 
presence of the HA phase in the disc, but the location of the HA in the discs is also very 
important. Also, when exclusive HA materials are used, the material must be sintered in 
order to provide mechanical strength and decrease solubility, therefore these characteristics 
needed to be reexamined for the composites. 
 The strength of the CaAlO phase is due to the hydrated phases that form during the 
casting process and interlock the different aggregates within the material. Despite the 
hydration steps in the HA casting phase, its strength comes from sintering and fusing the 
powders. Since the two materials being cast into one composite differ in their mechanism 
for obtaining strength, both processes were examined. Sintering the composites had a 
significant effect on the elastic modulus and modulus of rupture for the composites with 
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less than 5% HA. All of these composites had significantly reduced values as a result of 
sintering. This is due to the removal of the hydrating waters of the CaAlO phases. By 
driving these waters out of the composite at 1000°C, the CaAlO phases weaken and 
therefore weaken the composite as a whole. Conversely, when the 1-5% HA composites 
were simply hydrated and dried at room temperature, the elastic modulus and modulus of 
rupture was not affected. This is because the materials are between 95-99% CaAlO and 
CaAlO strength is the results of interlocked phases from hydration. Further when the elastic 
modulus of the composites was compared to non-load bearing cancellous bone, it was 
found that the 5, 10, 15, 20 and 25% HA composites were within the reported range of 3-
11 GPa.32,35 The 1-4% HA composites were very close to this value, no more than 4 GPa 
higher (observed with 2% HA). The modulus of rupture of non-load bearing cancellous 
bone is reported between 4-9 MPa.32,35 The 1 and 3-5% HA composites had moduli of 
rupture within this range and the 2% HA was 1 MPa higher. As the composites became 
>10% HA they were significantly lower than this range. Structural cancellous bone is 100% 
stronger than composites with >10% HA. Mechanical evaluation demonstrated that RT-
formed composites with between 1-5% HA were the most mechanically relevant materials 
to natural, structural cancellous bone.  
 The results of the mechanical evaluation indicated that the RT-formed 1-5% HA 
composites were mechanically similar to non-load bearing bone. The distribution of the 
HA phase within the cast composites is important to their success. The distribution is 
important for a few reasons, first, cellular interactions will take place at the scaffold-tissue 
interface, so when cast some HA must be present at the interface, and secondly because 
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sintering reduces the degradability of HA in vitro. But, since the composites were not being 
sintered, the presence of HA at the interface may lead to increased material degradability.  
 The presence and distribution of HA at the interface of all 1-5% HA composites 
was demonstrated using SEM-EDS. The EDS spectra collected on all composites revealed 
the presence of the elements calcium, aluminum, oxygen and phosphorus. Based on the 
data collected with PXRD, it can be established that the presence of phosphorus is the result 
of HA or the HA precursor and not starting Ca3(PO4)2 or any mixed calcium aluminum 
oxide-calcium phosphate phases. It was also found that as the amount of HA in the 
composite increases from 1% to 5% the interfacial amount of phosphorus increased. This 
indicates that by increasing the amount of Ca3(PO4)2 in the cast powder, the amount of HA 
at the interface will increase accordingly. This is important because it shows that the HA 
phase is distributed and abundant at the material-tissue interface. Furthermore, the 
degradability assay was carried out on the composite materials at physiological temperature 
and verified that the in vitro stability of the materials was not significantly affected. 
 
2.5 Conclusions 
 Composite materials consisting of calcium aluminum oxide and hydroxyapatite 
were successfully cast at room temperature to contain 1-5, 10, 15, 20 and 25% HA by mass. 
By casting the composites of CaAlO with small mass percentages of HA, the mechanical 
strength of the CaAlO material was not significantly affected. The 1-5% HA composites 
were up to 190% stronger than other composites and were better mechanical matches for 
non-load bearing cancellous bone. Importantly, the incorporated HA (1-5%) was present 
and distributed at the composite interface where cellular interactions could occur, and the 
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composites were stable in vitro in PBS at 37°C and 5% CO2 for 3 months. Based on these 
results the 1-5% HA composites were investigated for their ability to increase osteoblast 
response in vitro. 
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3 Chapter 3: Increased Osteoblast Response on 1-5% HA 
Composites  
3.1 Introduction 
 When synthetic bone graft materials are used they can lead to the formation of 
fibrous tissue around the implant which may inhibit new bone growth and integration at 
the graft-tissue interface.1-4 This encapsulation is caused by non-specific cell and protein 
adhesion due to the normal wound healing response.3 If fibrous encapsulation does occur 
it can lead to bone resorption at the graft-tissue interface which can lead to implant 
loosening and graft failure. One approach to increasing cell adhesion has been to link cell 
adhesion peptides to the surfaces of the graft materials.5-10 Initially studies demonstrated 
that the peptide RGD increased the attachment of a variety of cells (osteoblast, fibroblasts, 
mesenchymal stem cells) to an assortment of materials (calcium ceramics, titanium, 
polymers).5,11-14 The biggest issue with RGD is that it is a non-cell specific adhesion 
peptide and as a result it may lead to increased fibrous tissue at the graft-tissue 
interface.12,15-18 To address this, research has shifted to cell specific adhesion peptides.6,19 
The osteoblast specific adhesion peptide KRSR has been shown to bind an increased 
number of osteoblasts compared to unmodified surfaces (titanium, calcium ceramics).6,20-
22 KRSR has also been shown to preferentially bind osteoblasts over fibroblasts when 
immobilized to 100% CaAlO.6 These cell adhesion peptide based approaches do result in 
increased osteoblast response on modified materials, but materials based approaches have 
shown that calcium phosphate containing materials can increase osteoblast response.23-25  
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 Miljkovic and coworkers compared three calcium based ceramics in an in vivo rat 
calvarial critical-sized defect model.23 They compared CaAlO, RGD-modified CaAlO and 
a calcium phosphate, β-tricalcium phosphate, and demonstrated that CaAlO and RGD-
CaAlO did not have osteoconductive or osteoinductive properties on their own and both 
cause a mild immune reaction at the site of implantation.23 Conversely, the β-tricalcium 
phosphate did not illicit an immune response and showed signs of implant integration into 
the host tissue at 4 weeks.23 This work showed that unmodified calcium phosphate 
ceramics were a more viable option for increased in vivo bone regeneration over CaAlO 
and modified CaAlO.  
 Ball and coworkers used pulsed laser ablation as a method for deposition of HA 
onto titanium surfaces.24 Human osteoblasts were seeded onto the material surfaces and 
examined for a variety of cellular responses. The HA coated surfaces supported greater cell 
attachment, were more supportive of proliferation and growth and caused increased 
differentiation based on alkaline phosphatase presence.24 The osteoblasts on HA coated 
titanium also had a more organized actin cytoskeleton and had more contacts with the 
surface, determined by vinculin staining.24 They showed that by coating the mechanically 
strong titanium with a thin HA layer, the in vitro osteoblast performance was greatly 
improved. 
 Finally, Pino-Minguez and coworkers created composites of polymethyl-
methacrylate alone and mixed with HA in different concentrations.25 They examined 
composite PMMA:HA with 5%, 10%, 15% and 20% HA.25 PMMA has been studied due 
to its strength, however osteoblasts have shown limited activity when they are in contact 
with it, and it is common to observe fibroblastic cells at the PMMA-bone interface.25 
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PMMA:HA composites were investigated in an attempt to enhance the biocompatibility of 
the PMMA. They demonstrated the maximum amount of osteoblast growth and 
differentiation between 15% and 20% and that the transition between encapsulation and 
bone growth was at 15%.25 They revealed that by creating a composite of the mechanically 
strong PMMA and the osteoinductive HA, the in vitro bone cell response was significantly 
improved when the composites contained 15% and 20% HA. 
 In this study, the composite CaAlO:HA materials that were mechanically similar to 
non-load bearing bone (1-5% HA composites) were evaluated for their ability to increase 
in vitro osteoblast response. Based on the literature, it has been shown that the presence of 
calcium phosphates, either as β-tricalcium phosphate or HA, in biomaterials causes an 
increase in the biocompatibility of the coated or composite materials. Here, the effect of 
the addition of HA to the CaAlO material was examined through osteoblast attachment, 
viability and proliferation of cells seeded on the sterilized composites. 
 
3.2 Materials and Methods 
3.2.1 Materials 
 Calcium aluminum oxide (CaAlO) was supplied by Westmoreland Advanced 
Materials. Calcium phosphate tribasic (Ca3(PO4)2) and phosphate buffered saline (PBS, 
MgCl2 and CaCl2 free) were purchased from Sigma-Aldrich. Phosphoric acid was 
purchased from Fisher Scientific (Certified ACS). Normal human osteoblasts (NHOsts), 
osteoblast subculturing reagents (HEPES buffered saline, Trypsin/EDTA, Trypsin 
neutralizing solution) and osteoblast basal medium (OBM) were purchased from LONZA. 
The Live/Dead® Viability/Cytotoxicity assay kit and alamarBlue® reagent were 
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purchased from Life Technologies. All materials and chemicals were used as received 
unless otherwise noted. 
 
3.2.2 Casting Calcium-Based Ceramics 
3.2.2.1 Calcium Aluminum Oxide 
 Calcium aluminum oxide discs were prepared using the same method described in 
Chapter 2. The three different aggregate sizes of CaAlO utilized were -30+60, -60 and -
200, in a 1:1:2 ratio, that are previously separated using a sifting process that sorts out the 
particles based on their mesh size. The appropriate mass of each CaAlO aggregate size 
were thoroughly dry mixed at room temperature to ensure even particle distribution. 
Distilled deionized water (ddH2O) was then added to the aggregate powders at an amount 
equal to 0.3 mL of ddH2O per gram of CaAlO. The paste was allowed to thicken at room 
temperature for 10 minutes. Afterwards, the CaAlO was poured into either a 6x2 mm 
(diameter x height) cylindrical disc mold where it was allowed to set for four hours. The 
CaAlO casts were rehydrated in their molds with ddH2O, and allowed to set overnight. The 
next day the casts were hydrated in their molds using ddH2O, then allowed to set for the 
night. The following day casts were removed from their molds and immersed into ddH2O 
for 24 hours to ensure hydration of the material. CaAlO discs were sterilized before cellular 
studies by autoclaving at 121°C and 18 psi of steam for 60 minutes with fast exhaust.  
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3.2.2.2 Calcium Aluminum Oxide:Hydroxyapatite Composites 
 Calcium aluminum oxide:hydroxyapatite (HA) composite discs (1-5% HA) were 
cast using the same method described in Chapter 2. First the three different aggregate sizes 
of CaAlO (-30+60, -60 and -200) were dry mixed in a 1:1:2 ratio. Upon thorough mixing, 
ground Ca3(PO4)2 was added to the mixed CaAlO powder at a mass appropriate for the 
final composition to be 5% HA. The powders were thoroughly dry mixed together and 
hydrated with 0.3 mL of ddH2O per gram CaAlO and 1.1 mL H3PO4 per gram Ca3(PO4)2 
in the composite. The paste thickened for 10 minutes, then was poured into the 6x2 mm 
cylindrical molds. The paste set for four hours, then was rehydrated using H3PO4 and 
allowed to set overnight. Composites were hydrated again the next day with H3PO4 and 
permitted to set overnight. The following day composites were removed from the mold and 
rehydrated in H3PO4 for 24 hours. The 5% HA discs were sterilized before cellular and 
bacterial studies by autoclaving at 121°C and 18 psi of steam for 60 minutes with fast 
exhaust. 
 
3.2.3 Osteoblast Cell Culture 
 Normal human osteoblasts (NHOsts) isolated from a 2 year old male (LONZA) 
were thawed from a -200°C liquid N2 dewar and plated into T-25 cm
2 tissue culture flasks 
with at least 125,000 cells per flask in 5 mL of osteoblast basal medium (OBM). Tissue 
culture flasks were then placed into an incubator at 37°C and 5% CO2 for 24 hours, so live 
osteoblasts could adhere to the interior. In the flasks, osteoblast attachment and division 
was monitored daily until attached cells achieved approximately 80% confluence. OBM 
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was changed daily after initial seeding during the days leading up to 80% confluence in the 
flask. 
 Once cells reached 80% confluence they were subcultured out of the flasks and a 
cell trial was begun. Osteoblasts were subcultured according to the protocol provided by 
LONZA and counted using the hemocytometer with Trypan Blue. Nine autoclaved 
composite discs per time point (0-5% HA) were placed into individual wells of 48 well 
plates labeled as Days 1, 4 and 7. Osteoblasts were then diluted to 10,000 cells per mL in 
OBM, and 1 mL of this osteoblast solution was added to each well containing a disc. OBM 
was changed daily in the individual wells leading up to each time point. 
 
3.2.4 Osteoblast Attachment to 1-5% HA  
 NHOsts isolated from a 2 year old male were purchased from LONZA, cultured 
until 80% confluent and diluted to a concentration of 10,000 cells per mL of OBM. Three 
sample sets of three discs per time point (Days 1, 4 and 7, nine total discs) were autoclaved 
and seeded with 10,000 osteoblasts. After 1, 4 and 7 days the number of attached live and 
dead cells was determined using the Live/Dead® Viability/Cytotoxicity assay kit from Life 
Technologies (Figure 3.1).6,26-28 
 Using this assay kit, live cells will fluoresce green and dead cells will fluoresce red. 
Five spots on each sample with an area of 0.6 mm2 were imaged under 10x magnification 
using the Axioskop2 with AxioVision software and fluorescence filters. The number of 
live cells was then counted on all 45 images for each composite percentage for each day 
(1-5% HA), then normalized to the control 100% CaAlO. 
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Figure 3.1: Fluorescent based Live/Dead® Viability/Cytotoxicity assay where calcein AM 
enters a live cell and is digested by an esterase to result in the green fluorescent cells. The 
ethidium homodimer enters a dead cell and binds to the DNA in the nucleus resulting in 
the red fluorescent cells. 
   
3.2.5 Osteoblast Viability on 1-5% HA 
 NHOsts isolated from a 2 year old male were cultured and treated the same as 
described in Section 3.2.4. Cells were again assayed using the Live/Dead® 
Viability/Cytotoxicity assay kit and Axioskop2. In this assay, however, both the living 
(green) and dead (red) cells were counted on the 45 images of each composite for each day, 
getting a total number of cells. The percent viability was determined by dividing the 
number of live cells in each image by the total number of cells in each image.  
 
3.2.6 Osteoblast Proliferation on 1-5% HA 
 NHOsts isolated from a 2 year old male were cultured to 80% confluence and 
diluted to 10,000 cell per mL of OBM. Then 1 mL of the osteoblast solution was added to 
nine wells containing autoclaved discs (0-5% HA). Cell proliferation was evaluated using 
the alamarBlue® assay from Life Technologies (Figure 3.2).29-32 In this assay the 
Nucleus 
Esterase 
Calcein AM 
Calcein DNA Binding 
Ethidium Homodimer  
Live Cell Dead Cell 
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alamarBlue reagent, resazurin, is reduced to resorufin through metabolic processes that 
take place during cell division and the extent of reduction is correlated to the amount of 
cellular growth. The alamarBlue® reagent was added to the OBM in the wells in a 1:40 
dilution 24 hours prior to UV-VIS analysis on Days 1, 4 and 7. The absorbance of the 
alamarBlue reagent at 570 nm, corresponding to resorufin, was collected for all nine 
samples at each day using an Agilent Technologies Cary 100 UV-VIS spectrometer. The 
absorbance values of all of the composites on all days were normalized to the control 100% 
CaAlO. 
 
 
 
 
Figure 3.2: AlamarBlue® assay for osteoblast proliferation. If there are living, dividing 
cells in the wells, the alamarBlue® reagent is reduced and a color change can be observed 
and quantified by UV-VIS. If there are dead cells in the wells, the alamarBlue® reagent is 
not reduced. 
 
 
3.2.7 Statistics 
 A one-way analysis of variance (ANOVA) with a Bonferroni post-hoc test was used 
to determine the averages and statistical differences between the NHOst attachment, 
viability and proliferation at the p<0.05 level of significance and all data is reported as 
mean ± standard error. 
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NADP NADPH 
NAD NADH 
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3.3 Results 
3.3.1 Osteoblast Attachment to 1-5% HA 
 To determine if the incorporation of the osteogenic HA into the CaAlO:HA material 
increased osteoblast attachment over control 100% CaAlO, NHOsts (LONZA) were 
cultured and seeded onto autoclaved discs (0-5% HA). Nine sterilized discs per time point 
were placed into a 48 well plate and loaded with 10,000 NHOsts. After 1, 4 and 7 days the 
cells were imaged using the Live/Dead® Viability/Cytotoxicity assay kit (Figure 3.3). Five 
images per disc were collected and the number of live cells was normalized to CaAlO.  
 
 
 
 
 
 
 
 
Figure 3.3: Representative Live/Dead® fluorescent images of osteoblasts attached to 
control 100% CaAlO and 1-5% HA composites on Days 1, 4 and 7. 
 
 On Day 1 the normalized average number of live osteoblast cells per view was: 
control CaAlO: 100.0 ± 11.9; 1% HA: 96.4 ± 5.8; 2% HA: 101.5 ± 5.8; 3% HA: 96.0 ± 
5.9; 4% HA: 104.1 ± 4.8; 5% HA: 125.4 ± 6.0 (Figure 3.4). Only the 5% HA had a 
statistically greater number of attached live cells than control CaAlO.  
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Figure 3.4: Day 1 normalized average number of live osteoblasts attached to control and 
1-5% HA composites. * = statistically higher than control and all other composites. Data 
represented as mean ± standard error, p<0.05. 
 
 On Day 4 the normalized average number of live osteoblast cells per view was: 
control CaAlO: 100.0 ± 12.0; 1% HA: 141.9 ± 11.2; 2% HA: 146.2 ± 11.5; 3% HA: 143.2 
± 7.8; 4% HA: 145.8 ± 6.6; 5% HA: 185.7 ± 10.2 (Figure 3.5). Composites consisting of 
1-4% HA had a statistically greater number of live cells than control, but were equivalent 
to one another. However, the 5% HA composite exhibited statistically increased live 
osteoblast attachment when compared to both the control and the 1-4% HA composites. 
 
 
 
 
 
 
 
Figure 3.5: Day 4 normalized average number of live osteoblasts attached to control and 
1-5% HA composites. # = statistically higher than control and * = statistically higher than 
control and all other composites. Data represented as mean ± standard error, p<0.05. 
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 On Day 7 the normalized average number of live osteoblast cells per view was: 
control CaAlO: 100.0 ± 11.8; 1% HA: 121.2 ± 9.3; 2% HA: 124.7 ± 6.8; 3% HA: 126.4 ± 
8.9; 4% HA: 117.4 ± 5.4; 5% HA: 142.4 ± 5.6 (Figure 3.6). Composites with 1-4% HA 
had a statistically greater number of live cells when compared to control CaAlO, but similar 
to Day 4 they were all statistically equal to one another. The 5% HA had a statistically the 
greater number of live cells than the control CaAlO and 1-4% HA composites.  
 
 
 
 
 
 
Figure 3.6: Day 7 normalized average number of live osteoblasts attached to control and 
1-5% HA composites. # = statistically higher than control and * = statistically higher than 
control and all other composites. Data represented as mean ± standard error, p<0.05. 
 
3.3.2 Osteoblast Viability on 1-5% HA 
 To examine the effect of HA on osteoblast viability, NHOsts (LONZA) were 
cultured and seeded onto autoclaved discs (0-5% HA). Nine sterilized discs per time point 
were placed into a 48 well plate and loaded with 10,000 NHOsts. After 1, 4 and 7 days the 
cells were imaged using the Live/Dead® Viability/Cytotoxicity assay kit. Five images per 
disc were collected. The number of live cells was divided by the total number of cells to 
determine the percent viability of the attached NHOsts.  
 On Day 1 the percent cell viability was: control CaAlO: 60.7 ± 4.7; 1% HA: 73.2 
± 2.3; 2% HA: 67.6 ± 2.5; 3% HA: 67.8 ± 2.5; 4% HA: 81.4 ± 1.6; 5% HA: 83.0 ± 1.7 
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(Figure 3.7). The 1%, 4% and 5% HA composites had statistically higher percent cell 
viability than control CaAlO. The 2% and 3% HA composites did not have an increased 
percent cell viability on Day 1 over control.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Day 1 percent viability of attached cells on control and 1-5% HA composites. 
# = statistically higher than control. Data represented as mean ± standard error, p<0.05. 
 
 The percent cell viability on Day 4 was: control CaAlO: 57.5 ± 4.2; 1% HA: 74.2 
± 2.3; 2% HA: 77.0 ± 2.5; 3% HA: 81.6 ± 1.6; 4% HA: 79.5 ± 1.6; 5% HA: 81.7 ± 2.1 
(Figure 3.8). All of the 1-5% HA composites had statistically increased percent cell 
viability when compared to control CaAlO.  
 
 
 
 
 
 
 
 
Figure 3.8: Day 4 percent viability of attached cells on control and 1-5% HA composites. 
# = statistically higher than control. Data represented as mean ± standard error, p<0.05. 
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 On Day 7 the percent cell viability was: control CaAlO: 69.6 ± 4.2; 1% HA: 81.2 
± 2.8; 2% HA: 88.1 ± 1.5; 3% HA: 84.6 ± 1.9; 4% HA: 87.6 ± 1.3; 5% HA: 84.9 ± 1.6 
(Figure 3.9). Again, the percent viability was significantly higher on all of the composites 
compared to control CaAlO.  
 
 
 
 
 
 
Figure 3.9: Day 7 percent viability of attached cells on control and 1-5% HA composites. 
# = statistically higher than control. Data represented as mean ± standard error, p<0.05. 
 
3.3.3 Osteoblast Proliferation on 1-5% HA 
 To determine if the presence of HA had an effect on osteoblast proliferation, 
NHOsts were cultured and seeded onto sterilized discs (0-5% HA). Nine discs at each time 
point were placed into 48 well plates and loaded with 10,000 NHOsts. Before evaluating 
osteoblast proliferation, the alamarBlue® reagent was diluted in the OBM. After 1, 4 and 
7 days the OBM was examined using UV-VIS spectroscopy (Figure 3.10). The absorbance 
of the OBM from each well was collected and normalized to control CaAlO. 
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Figure 3.10: Representative OBM solutions for Day 7 of the alamarBlue® assay for 
control and 1-5% HA.  
 
 On Day 1 the normalized average absorbance was: control CaAlO: 1.00 ± 0.02, 1% 
HA: 1.00 ± 0.03, 2% HA: 1.06 ± 0.02, 3% HA: 1.12 ± 0.03, 4% HA: 1.24 ± 0.02, and 5% 
HA: 1.22 ± 0.03 (Figure 3.11). Based on the absorbance, the 4% and 5% HA composites 
exhibited a statistically greater amount of cell proliferation compared to all other samples, 
while the 2% and 3% HA were higher than 1% HA and control.  
 
 
 
 
 
 
Figure 3.11: Day 1 normalized absorbance at 570 nm of control and 1-5% HA composites. 
# = statistically higher than control. Data represented as mean ± standard error, p<0.05. 
  
 All of the composites had significantly increased cell proliferation compared to 
control by Day 4, however the 5% HA supported the greatest amount of proliferation. The 
normalized average absorbance on Day 4 was: control CaAlO: 1.00 ± 0.01, 1% HA: 1.09 
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± 0.02, 2% HA: 1.12 ± 0.01, 3% HA: 1.12 ± 0.01, 4% HA: 1.14 ± 0.02, and 5% HA: 1.20 
± 0.03 (Figure 3.12). 
 
 
 
 
 
 
Figure 3.12: Day 4 normalized absorbance at 570 nm of control and 1-5% HA composites. 
# = statistically higher than control and * = statistically higher than control and all other 
composites. Data represented as mean ± standard error, p<0.05. 
 
 At Day 7 the normalized average absorbance was: control CaAlO: 1.00 ± 0.02, 1% 
HA: 1.22 ± 0.02, 2% HA: 1.23 ± 0.02, 3% HA: 1.34 ± 0.04, 4% HA: 1.41 ± 0.06 and 5% 
HA: 1.51 ± 0.03 (Figure 3.13). Similar to Day 4, all of the composites exhibited 
significantly greater cell proliferation than the control CaAlO. The cells on the 5% HA 
composite again supported the highest amount of proliferation. 
 
 
 
 
 
 
 
 
 
Figure 3.13: Day 7 normalized absorbance at 570 nm of control and 1-5% HA composites. 
# = statistically higher than control and * = statistically higher than control and all other 
composites. Data represented as mean ± standard error, p<0.05. 
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3.4 Discussion 
 The osteogenic HA phase was shown to be present at the composite surface without 
adversely affecting the mechanical integrity of the material. In vitro osteoblast tests 
examined if increasing the amount of HA at the interface played a significant role in bone 
cell performance when cultured on the composites. The composites were evaluated for 
their ability to increase osteoblast attachment and percent viability, and their ability to 
support increased cell proliferation. If the presence of the osteoinductive HA at the 
interface plays a significant role in the osteoblast response, the materials with increasing 
amounts of HA should result in the best composite material. 
 On the extended time points of the osteoblast assays (Days 4 and 7), the 5% HA 
composites had the greatest number of attached live cells and supported the greatest amount 
of cell proliferation, compared to control CaAlO and the 1-4% HA composites. Whereas 
the percent viability of attached cells was increased on all composites over control CaAlO. 
The greatest increase in cell attachment and proliferation on the 5% HA is the result of the 
exposure of the cells to the osteoconductive and osteoinductive HA at the tissue-material 
interface. This result is in agreement with the work of Pino-Minguez and coworkers, where 
they demonstrated the maximum amount of osteoblast growth, proliferation and 
differentiation at higher percentage composites of PMMA and HA.25 In their work, they 
observed the maximum cellular response between 15% and 20% HA, and found that at 
greater than 20% HA the PMMA:HA composites lost their mechanical integrity.25    
 Based on the physical and biological evaluation of the 1-5% HA composites, the 
5% HA composite is the most applicable for a cancellous bone scaffold material. The 5% 
HA had an elastic modulus and modulus of rupture similar to non-load bearing cancellous 
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bone and consistently resulted in increased osteoblast attachment, viability and 
proliferation on all days examined. This composite was the only one to enhance cellular 
response on each day examined. These results are in agreement with previous work in the 
literature that has demonstrated that composite materials containing HA increase bone 
regeneration more than the non-HA containing materials.23-25 Further, this CaAlO:HA 
composite material is mechanically stronger than HA alone and is easier to synthesize. 
 More importantly, in the past increased in vitro osteoblast performance and in vivo 
bone regeneration using CaAlO based materials required interfacial modification with 
biomolecules.6,23,28,33 Various organic molecules, cell adhesion peptides and osteogenic 
proteins have been immobilized to the CaAlO in order to increase bone cell 
response.6,23,28,33 A result of the necessity to chemically modify the material is multiple 
synthetic reaction steps. These synthetic steps may introduce harmful chemicals to the 
materials, result in the deactivation of the linked biomolecule or require two separate 
reaction systems to simultaneously immobilize multiple functionalities on the 
material.6,23,28,33 In using this materials-based approach, where composites that contain HA 
at the interface, bone cells are able to perform significantly better than control samples and 
interfacial modification of the material is not required.25 
 
3.5 Conclusions 
 In vitro osteoblast attachment, percent viability and proliferation were all 
successfully enhanced on the RT formed 1-5% HA composites. Through the incorporation 
of osteogenic HA into the composite, and the HA phase presence at the material interface 
(confirmed using SEM-EDS) all of the indicators of cellular response were improved 
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compared to 100% CaAlO at the extended time points, Days 4 and 7. Further, the 5% HA 
composite was the only material that resulted in increased cell attachment, percent viability 
and proliferation at the short time point, Day 1. Not only was the 5% HA the only material 
to mechanically match the elastic modulus and modulus of rupture of non-load bearing 
cancellous bone, but it was also the only material that significantly increased osteoblast 
attachment, percent viability and proliferation on all days examined. Based on these results 
the 5% HA is the appropriate CaAlO:HA composite to use when increased cellular 
response is desired on mechanically relevant materials. 
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Chapter 4: Creating a Multifunctional Composite Ceramic by 
Antimicrobial Peptide Immobilization to the 5% HA 
4.1 Introduction 
 The formation of bacterial biofilms on the surfaces of medical implants is a serious 
clinical problem that may result in infection, implant failure, revision surgery and      
death.1-7 Between 5-14% of initial orthopedic joint replacement surgeries result in implant 
failure.8-10 Bacterial biofilms are chronic infections that occur on implant surfaces and are 
one of the most serious causes of implant failure.11-13 Infection typically occurs at the time 
of surgery, where bacteria on the skin can enter the wound and colonize the implant 
surface.3,12-17 Therefore, limiting bacterial attachment to the implant is important in limiting 
implant failure.  
 Upon attachment the planktonic bacteria undergo a phenotype change into sessile 
organisms which produce a protective polysaccharide matrix and have a reduced need for 
nutrients.14,16,18 The extracellular matrix protects the bacteria from their surrounding 
environment, including any antibiotics that may be employed for treatment.19-21 Further, 
the matrix-enclosed bacteria can spread to other regions of the body, through shedding of 
biofilm clusters or the release of planktonic cells, making it difficult to determine the 
infection location and can lead to severe infections and even death (Figure 4.1).2,10,13,14,17,22 
Conventional treatments are frequently insufficient because they require high doses of 
antibiotics and contribute to antibiotic resistance in the biofilm.5,23-26 Frequently the only 
way to treat a biofilm infection is to remove the implant and install a new one, however 
this does not eliminate the risk of re-infection of the new material.12,13,15,17,27  
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Figure 4.1: Steps in biofilm formation on the implant surface include irreversible bacterial 
attachment of planktonic bacteria, bacterial replication and polysaccharide matrix 
production and shedding of biofilm clusters and release of planktonic cells.  
 
 Since the bacteria within the biofilm are sessile and tend to not grow and divide, 
current research aims to prevent biofilm formation by limiting the initial bacterial 
attachment.28-30 Some approaches include the use of physical adsorption of antibiotics into 
the biomaterials, that way when placed into the physiological environment, the antibiotics 
leach from the material and treat the bacteria that are in the biomaterials vicinity.31-33 In 
using this approach, groups have seen that the majority of the antibiotics tend to release 
from the material very rapidly and do not remain localized to surgical site.34,35 In other 
studies, antibiotics have been covalently immobilized to the materials in an attempt to keep 
the treatment localized to the surgical site.36,37 Many studies have shown that this approach 
keeps the antibiotic localized to the material and that the antibiotics maintain some form of 
activity against bacterial challenge.36,37 However, other work has shown that the 
immobilization of antimicrobials reduces their effectiveness against bacteria.38 Also, 
reaction schemes must be developed that use functional groups within the antibiotic that 
are not part of the mechanism of action, and because the antibiotics have specific modes of 
action, the orientation of the immobilized molecules must be considered.39,40 
Irreversible attachment Replication and Matrix 
production 
Shedding and Release 
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 As an approach to limit the risk of development of antibiotic resistant bacterial 
strains, antimicrobial peptides (AMP) are being investigated.41-43 AMPs are short peptides 
that are part of the innate immune response to pathogens.44 Many AMPs have broad 
spectrum efficacy against both gram positive and gram negative bacteria.44,45 Most 
importantly AMPs have low minimum inhibitory concentrations and a fast-acting 
mechanism.44 AMPs form membrane pores that compromise cell viability, this is important 
in biofilm applications because the AMP mechanism of action does not rely on bacteria 
growth and division like it does in many common antibiotics (Figure 4.2).44,46-48 
 
 
 
 
 
 
 
 
Figure 4.2: A proposed mechanism of AMP action is membrane pore formation where 
hydrophobic amino acids allow for intercalation of the peptide into the phospholipid 
membrane of bacteria, and hydrophilic amino acids form the interior of the pore. 
 
 Inverso-CysHHC10 is a synthetic AMP (H-CKRWWKWIRW-NH2, all D-amino 
acids, Scheme 4.1) shown to be highly effective against common biofilm forming bacteria 
either when in solution or when covalently incorporated into a flexible polyethylene glycol 
hydrogel.49,50 HHC10 has an LC99.9 (lethal concentration to 99.9% of inocula) of 8 μM 
against the common biofilm forming bacteria, S. aureus, S. epidermidis and E. coli.49,50 
Antimicrobial peptide with 
hydrophobic (blue) and hydrophilic 
(red) amino acid residues. 
Cell Exterior 
Cell Interior 
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HHC10 is also proteolytically stable because it is composed of the nonproteinogenic D-
amino acids. It has been shown that greater than 90% of HHC10 remains intact after 
soaking in pooled human serum for 25 hours.49 The HHC10 was also shown to be non-
cytotoxic to sheep erythrocytes, as only 1% of the initially seeded cells did not survive after 
incubation with HHC10.49 Lastly, HHC10 has been amended to include the cysteine 
residue at the N-terminus of the peptide. Cleophas et al demonstrated that the addition of 
this cysteine residue does not affect the activity of the AMP in solution, and the cysteine 
residue facilitates the ease of immobilization of HHC10 to materials.50 
 
 
 
 
 
Scheme 4.1: Inverso-CysHHC10 containing the hydrophobic tryptophan and isoleucine 
amino acids and hydrophilic arginine and lysine amino acids. The sacrificial cysteine is 
appended to the N-terminus.   
 
 The goal in this work was to covalently attach HHC10 to the mechanically 
optimized and biologically preferred 5% HA composite to add antimicrobial properties to 
the synthetic graft material. Each of the two steps in the attachment were verified using 
DRIFT and the activity of the linked HHC10 against E. coli was evaluated using the NPN 
uptake assay and a bacterial turbidity test. Lastly, in an ideal multifunctional system the 
function of one modification should not affect the function of another. Therefore osteoblast 
performance on the HHC10 modified 5% HA discs was also re-examined. 
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4.2 Materials and Methods 
4.2.1 Materials 
 Calcium aluminum oxide (CaAlO) was supplied by CAberTech, Inc. (Monessen, 
PA). Calcium phosphate tribasic and 2-hydroxy-4’-(2-hydroxyethoxy)-2-
methylpropiophenone (Irgacure 2959, 98%) were purchased from Sigma-Aldrich. 
Phosphoric acid (Certified ACS), tetrahydrofuran (THF, Optima, 99.9%) and 4-(2-
hydroxyethyl)-piperazine ethanesulfonic acid (HEPES, 99%) were obtained from Thermo 
Fisher Scientific. The THF was distilled over sodium and benzophenone prior to use. 16-
heptadecenoic acid (16-ene, 97%) was purchased from Apollo Scientific and N,N-
dimethylformamide (DMF, 99.8%) from Acros Organics. The antimicrobial peptide, 
Inverso-CysHHC10, (HHC10, >90.0%, H-CKRWWKWIRW-NH2) was obtained from 
GenScript USA, Inc. as a lyophilized powder and reconstituted in doubly distilled water 
(ddH2O). N-phenylnaphthylamine (NPN, 98%) was purchased from Ultra Scientific and 
Luria Bertani medium (LB media) was from MP Biomedicals. The LB media capsules 
were dissolved in 50 mL of ddH2O and autoclaved before use. Escherichia coli (ATCC® 
25922) was obtained from ATCC. Normal human osteoblasts, osteoblast subculturing 
reagents (HEPES buffered saline, Trypsin/EDTA, Trypsin neutralizing solution) and 
osteoblast basal medium (OBM) were purchased from LONZA (Walkersville, MD). The 
Live/Dead® Viability/Cytotoxicity Assay Kit and alamarBlue® reagent were purchased 
from Life Technologies. All materials and chemicals were used as received unless 
otherwise noted. 
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4.2.2 Casting Composite 5% HA 
 Calcium aluminum oxide:hydroxyapatite (HA) composite discs (5% HA only) 
were cast using the same method previously described in Chapter 2 and 3. First the three 
different aggregate sizes of CaAlO (-30+60, -60 and -200) were dry mixed in a 1:1:2 ratio. 
Upon thorough mixing, ground Ca3(PO4)2 was added to the mixed CaAlO powder at a mass 
appropriate for the final composition to be 5% HA. The powders were thoroughly dry 
mixed together and hydrated with 0.3 mL of ddH2O per gram CaAlO and 1.1 mL H3PO4 
per gram Ca3(PO4)2 in the composite. The paste thickened for 10 minutes, then was poured 
into the 6x2 mm cylindrical molds. The paste set for four hours, then was rehydrated using 
H3PO4 and allowed to set overnight. Composites were hydrated again the next day with 
H3PO4 and permitted to set overnight. The following day composites were removed from 
the mold and rehydrated in H3PO4 for 24 hours. The 5% HA discs were sterilized before 
cellular and bacterial studies by autoclaving at 121°C and 18 psi of steam for 60 minutes 
with fast exhaust. 
 
4.2.3 Covalent Antimicrobial Peptide Immobilization 
 The antimicrobial peptide Inverso-CysHHC10 was attached to the 5% HA surface 
using a two-step solution deposition method.  First, warm (60°C) 5% HA discs were 
immersed in a 1 mM 16-heptadecenoic acid (16-ene) solution (dry THF) for one hour at 
room temperature. Excess solvent was removed by placing the discs on a 0.1 torr vacuum 
line for 24 hours. The 16-ene modified discs were then placed into a solution of 1 mg/mL 
HHC10 and 0.5 mg/mL Irgacure 2959 in 10:1 ddH2O:DMF.
51 The HHC10 solution 
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containing the 16-ene modified discs was then reacted under 365 nm UV light for 3 hours 
with N2 purge. Again, excess solvent was removed on a 0.1 torr vacuum line for 24 hours 
(Scheme 4.2). Both 16-ene and HHC10 modified 5% HA discs were rinsed in solvent prior 
to analysis. Discs were sterilized by autoclaving at 121°C and 18 psi of steam for 60 
minutes with fast exhaust prior to cellular and bacterial assays. 
 
 
 
 
 
Scheme 4.2: Reaction sequence utilized for the covalent immobilization of HHC10 to 
composite 5% HA. First the material is modified with 16-heptadecenoic acid, then an 
alkene-thiol click reaction is used to link HHC10 at the interface. 
 
4.2.4 Diffuse Reflectance Infrared Fourier Transform 
Spectroscopy 
 A Thermo Nicolet Nexus 470 FT-IR spectrophotometer equipped with a diffuse 
reflectance attachment was used to obtain spectra of the modified composites following 
each step of HHC10 immobilization. Each step of the covalent modification served as the 
background spectra for the subsequent step in the sequence. Spectra were collected for 
1024 spectral scans (4000-400 cm-1) with a resolution of 4 cm-1. 
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4.2.5 Quantification of Antimicrobial Peptide Immobilization 
on 5% HA 
 Using a Horiba Scientific Fluoromax-4 Spectrofluorometer, the amount of HHC10 
immobilized to the 5% HA was measured. Quantification using fluorimetry was possible 
because HHC10 contains four tryptophan residues, with the fluorescent indole side chain, 
and an excitation wavelength of 285 nm.52,53 A five point calibration curve with stock 
concentrations of 0.025, 0.050, 0.075, 0.100 and 0.200 mg of HHC10 per mL of 10:1 
ddH2O:DMF was prepared (n=5 per concentration). The stock solutions were prepared 
using the same reaction conditions that were used to immobilize HHC10 to the 5% HA, 
described in Section 4.2.3. Fluorescence emission spectra were collected from 250-450 nm 
with the maximum emission used for quantification observed at 342 nm. Ten HHC10 
modified 5% HA discs were prepared using a 1 mg/mL HHC10 solution with 0.5 mg/mL 
Irgacure 2959 in 10:1 ddH2O:DMF and 16-heptadecenoic acid modified 5% HA discs 
(prepared as described in Section 4.2.3). After the immobilization reaction was complete, 
the 5% HA discs were removed from the solution and the solution fluorescence was 
collected. The concentration of HHC10 remaining in the solution was quantified using the 
calibration curve. The resulting average change in concentration from before HHC10 
immobilization to after was correlated to how much HHC10 had been immobilized to the 
5% HA discs (n=10). 
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4.2.6 Quantification of Antimicrobial Peptide Released from 
Modified 5% HA 
 To quantify the amount of HHC10 that remained immobilized to the 5% HA discs, 
direct infusion mass spectrometry was used. Six HHC10 modified 5% HA discs were 
soaked in 2 mL of ddH2O for 1, 3.5 and 24 hours. At each time point the discs were 
removed from the water and moved into a fresh 2 mL of ddH2O. The ddH2O from each 
time point was filtered using a 0.2 μm syringe filter and 0.1% formic acid (total volume) 
was added to assist in the HHC10 ionization process. A five point calibration curve based 
on the instrument signal at [HHC10+3H]3+ was prepared with concentrations of 9.0x10-9, 
5.0x10-8, 1.5x10-7, 3.0x10-7 and 5.0x10-7 M, all with 0.1% formic acid (n=5 per 
concentration). The six samples at each time point were then analyzed with an Agilent 
Technologies 6530 Accurate-Mass Quadrupole-Time of Flight Liquid 
Chromatography/Mass Spectrometry (Q-TOF MS) with High Performance Liquid 
Chromatography-Chip Cube Mass Spectrometry Interface using an FIA-Chip (II). Samples 
were analyzed in positive ionization mode using the following instrument settings: Gas 
temperature=325°C, Drying gas=4.0 L/min, Capillary voltage=1900 V, Fragmentor 
voltage=175 V, Skimmer voltage=65 V and Octapole1 voltage=750 V. Sample and stock 
solutions were subtracted from a ddH2O and 0.1% formic acid background and the 
concentration of HHC10 in solution was quantified using the calibration curve (n=6). 
Based on the volume of the samples, the mass of HHC10 in solution was determined and 
the percent of HHC10 remaining linked after soaking was calculated based on the amount 
immobilized determined in Section 4.2.5.  
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4.2.7 Escherichia coli Culture 
 Escherichia coli (E. coli) purchased for American Type Culture Collection 
(ATCC® 25922) were thawed from a -80°C freezer and placed into a T-25 cm2 cell culture 
flask. One full inoculation loop of E. coli was added to 15 mL of the prepared LB media 
and placed onto the shaker incubator. Flasks of E. coli were left in the shaker incubator 
long enough to grow to an optical density at 600 nm (OD600 nm) of 0.5 for the N-
phenylnaphthylamine uptake assay and 0.1 for the bacterial turbidity test.  
 
4.2.8 Escherichia coli NPN Uptake Factor on Modified 5% HA 
 A fluorescence assay based on the uptake of a nonpolar probe, N-
phenylnaphthylamine (NPN), was used to monitor the changes in permeability of the 
membrane of E. coli when mixed with HHC10 modified 5% HA discs.54,55 If the bacteria 
membrane is compromised, NPN enters the phospholipid environment and increased 
fluorescence can be observed (Figure 4.3).  
 
 
 
 
 
 
Figure 4.3: NPN uptake assay for determination of E. coli membrane permeability. If the 
HHC10 effectively lyses the membrane the NPN can enter the hydrophobic environment 
and increased fluorescence of NPN can be observed. If the membrane remains intact the 
NPN cannot enter and fluorescence is not observed.  
 
λ
ex
 = 355 nm 
λ
em
 = 405 nm 
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 A planktonic E. coli culture was grown to an initial optical density at 600 nm  
(OD600 nm) of 0.5 in Luria-Bertani media (LB media). The cells were centrifuged for 10 
minutes at 1000 g, then resuspended in one-half of their initial volume of 5 mM HEPES at 
pH 7.2. A 5 mM NPN solution, in acetone, was prepared, and diluted to 40 μM with HEPES 
immediately before use. 
 For a standard fluorescence measurement using the PerkinElmer VICTOR3 
Multilabel Plate Reader, the microtitre plate wells (ten/sample) were supplemented with 
200 μL total of HEPES, E. coli, NPN and 5% HA discs, dependent on the sample. Wells 
that contained E. coli and NPN always had 100 μL and 50 μL respectively, with HEPES 
accounting for the remaining volume. Sample wells were (i) HEPES + unmodified 5% HA 
disc; (ii) HEPES + NPN + unmodified 5% HA disc; (iii) HEPES + E. coli + unmodified 
5% HA disc; (iv) HEPES + E. coli + NPN + unmodified 5% HA disc; (v) HEPES + E. coli 
+ HHC10 modified 5% HA disc; (vi) HEPES + E. coli + NPN + HHC10 modified 5% HA 
disc. The E. coli solution was always added last, immediately preceding fluorescent 
measurement, and the values were collected within three minutes of E. coli addition. The 
NPN uptake factors were then calculated as a ratio of background-corrected (subtracted by 
the value in the absence of NPN) fluorescence values of the E. coli suspension and of the 
HEPES buffer.54,55 The NPN uptake factor of the treated E. coli was normalized to the NPN 
uptake factor of untreated E. coli (n=1000).  
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4.2.9 Escherichia coli Bacterial Turbidity Tests with Modified 
5% HA 
 An analysis based on bacterial optical density was used to monitor the effect of 
immobilized HHC10 on the growth of the gram-negative E. coli (Figure 4.4).36,56 A 
planktonic culture of E. coli was diluted to an initial OD600 nm of 0.1 in LB media. Two 
milliliters of the planktonic E. coli solution were placed into 15 mL centrifuge tubes. There 
were four tubes of each sample: (i) E. coli + unmodified 5% HA disc and (ii) E. coli + 
HHC10 modified 5% HA disc. After preparing the samples, the centrifuge tubes were 
placed in a shaker incubator at 37°C for 2.5 hours. After the incubation period, the OD600 
nm of each sample was recorded using an Agilent Technologies Cary 100 UV-VIS 
spectrometer. Three replicates of each sample were collected and the average OD600 nm of 
HHC10 modified 5% HA (ii) treated E. coli was normalized to the untreated E. coli (i).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Bacterial turbidity test for the evaluation of E. coli growth in culture. If HHC10 
reduces bacterial growth, the concentration of E. coli in solution will be smaller and the 
OD 600 nm will be lower than untreated bacteria.  
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4.2.10 Inverso-CysHHC10 Antimicrobial Activity in Solution 
and on Modified 5% HA  
 Using the NPN uptake factor and bacterial turbidity tests previously described in 
Section 4.2.8 and 4.2.9, the efficacy of the immobilized HHC10 against E. coli was 
compared to the free, in solution HHC10 to determine the concentration dosage that the 
linked AMP was equally as effective as. 
 In the NPN assay eight samples were prepared and treated using the same 
approach.54,55 The first six samples were the same as those in Section 4.2.8 and now 
included (vii) HEPES + E. coli + 10 μM HHC10 solution (50 μL) + unmodified disc and 
(viii) E. coli + 10 μM HHC10 solution (50 μL) + NPN +  unmodified 5% HA. The NPN 
uptake factors were calculated using the same method and the treated E. coli (both 10 μM 
solution and linked to 5% HA) were normalized to the untreated E. coli.  
 In the bacterial turbidity test, the bacteria was prepared using the same method and 
the two samples in Section 4.2.9 were the same and one additional sample was added (iii) 
E. coli + 10 μM HHC10 + unmodified 5% HA disc.36,56 The average OD600 nm of the treated 
E. coli (both solution and linked) was normalized to the untreated E. coli.  
 
4.2.11 Osteoblast Cell Culture 
 NHOsts isolated from a 2 year old male were thawed from a -200°C liquid N2 dewar 
and plated into T-25 cm2 tissue culture flasks with at least 125,000 cells per flask in 5 mL 
of OBM. Tissue culture flasks were placed into an incubator at 37°C and 5% CO2 for 24 
hours so live osteoblasts could adhere to the interior. In the flasks, NHOst attachment and 
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division was monitored daily until approximately 80% confluence. OBM was changed 
daily after initial seeding during the days leading up to 80% confluence in the flask. 
 Once cells reached 80% confluence they were subcultured out of the flasks and a 
cell trial was begun. NHOsts were subcultured according to the protocol provided by 
LONZA and counted using the hemocytometer with Trypan Blue. Nine autoclaved HHC10 
modified 5% HA discs per time point were placed into individual wells of 48 well plates 
labeled as Days 1, 4 and 7. NHOsts were then diluted to 10,000 cells per mL in OBM, and 
1 mL of this NHOst solution was added to each well containing a disc. OBM was changed 
daily in the individual wells leading up to each time point. 
 
4.2.12 Osteoblast Attachment to Modified 5% HA 
 NHOsts isolated from a 2 year old male were purchased from LONZA, cultured 
until 80% confluent and diluted to a concentration of 10,000 cells per mL of OBM. Three 
sample sets of three discs per time point (Days 1, 4 and 7, nine total discs) were autoclaved 
and seeded with 10,000 NHOsts. After 1, 4 and 7 days the number of attached live and 
dead cells was determined using the Live/Dead® Viability/Cytotoxicity assay kit from Life 
Technologies.56-59 The number of live cells was counted on all 45 images for control 
unmodified 5% HA and HHC10 modified 5% HA. The amount of attached lived cells on 
HHC10 modified 5% HA was normalized to the control unmodified 5% HA. 
 
4.2.13 Osteoblast Viability on Modified 5% HA 
 NHOsts isolated from a 2 year old male were cultured and treated the same as 
described in Section 4.2.11. Cells were again assayed using the Live/Dead® 
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Viability/Cytotoxicity assay kit and both the living (green) and dead (red) cells were 
counted on the 45 images collected for control and HHC10 modified 5% HA, obtaining a 
total number of cells. The number of live cells was divided by the number of total cells to 
determine percent viability.  
 
4.2.14 Osteoblast Proliferation on Modified 5% HA 
 NHOsts isolated from a 2 year old male were cultured to 80% confluence and 
diluted to 10,000 cell per mL of OBM. Then 1 mL of the NHOst solution was added to 
nine wells containing autoclaved 5% HA discs. NHOst proliferation was evaluated using 
the alamarBlue® assay from Life Technologies.14,60-63 The absorbance of the alamarBlue 
reagent in the OBM was collected for all nine samples at each time point. The absorbance 
of the OBM from the HHC10 modified 5% HA was normalized to the control unmodified 
5% HA. 
 
4.2.15 Statistics 
 A one-way analysis of variance (ANOVA) with a Bonferroni post-hoc test was used 
to determine the averages and statistical differences between the HHC10 immobilization 
and amount released, the E. coli NPN uptake factor and OD600 nm for linked and free 
HHC10, and the NHOst attachment, viability and proliferation all at the p<0.05 level of 
significance and all data is reported as mean ± standard error. 
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4.3 Results 
4.3.1 Covalent Antimicrobial Peptide Immobilization 
 To add antimicrobial activity to the 5% HA composite HHC10 was covalently 
immobilized to the surface. The covalent linkage of HHC10 to the 5% HA controls the 
location of the antimicrobial, resulting in a localized treatment aimed at preventing 
bacterial colonization and possible biofilm formation. The 5% HA composite was the only 
composite evaluated due to its mechanical similarity to non-loading bearing bone (Chapter 
2) and the consistent, increased osteoblast attachment and proliferation on all days 
examined (Chapter 3).  
 To immobilize HHC10 to the surface of the 5% HA discs, warm (60°C) samples 
were immersed in a 1 mM solution of 16-ene (THF) for 1 hour at room temperature. 
Samples were removed from solution and placed onto a 0.1 torr vacuum line for 24 hours. 
The modified samples were analyzed using diffuse reflectance infrared Fourier transform 
(DRIFT) spectroscopy. The peaks corresponding to the asymmetric and symmetric 
methylene stretches, at 2921 and 2852 cm-1, confirm the presence of the 16-ene on the 
surface (Figure 4.5).36,56,59 The peak positions are indicative of an organic acid film that 
contains gauche and trans interactions. The presence of both types of interactions is a result 
of the surface topography of the 5% HA material, observed using SEM.  
 The acid head group binding mode and tail group functionality was determined by 
looking at the carboxylic acid region of the DRIFT spectrum (Figure 4.5). The solid 16-
ene spectrum contains peaks at 1709, 1434 and 1295 cm-1 corresponding to the νC=O, vC-O 
and vC-O-H of the free carboxylic acid and the peak attributed to the vC=C at 1642 cm
-1. The 
spectrum of the modified substrate contains a broad peak centered at 1540 cm-1 that is the 
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result of the carboxylate stretch, which indicates a bidentate organic acid binding mode. 
Most importantly, the immobilized acid spectrum also contains a peak at 1651 cm-1 which 
is attributed to the alkene (vC=C), free at the film interface that may be used for subsequent 
organic reactions. 
 
 
 
 
 
 
 
Figure 4.5: DRIFT spectra indicating successful surface modification of 5% HA with 16-
heptadecenoic acid. A) Methylene stretching region, νCH2 asymm= 2921 cm-1 and νCH2 symm= 
2852 cm-1 indicating the presence of the acid film after solvent rinse. B) Acid head group 
binding region with peaks indicative of a bidentate binding mode for the attached acid (red 
spectra) at 1558, 1538 and 1521 cm-1 and the free interfacial νC=C at 1651 cm-1. 
 
 The immobilization of HHC10 was achieved using a one-step alkene-thiol click 
reaction, where a sacrificial cysteine residue (thiol side chain) appended to the AMP reacts 
with the terminal alkene of the formed film. 16-ene modified 5% HA discs were placed in 
a 1 mg/mL HHC10 solution containing 0.5 mg/mL Irgacure 2959 in 10:1 ddH2O:DMF.
51 
The HHC10 solution, containing the 16-ene modified 5% HA discs, was reacted under 365 
nm UV light for 3 hours with N2 purge. The successful linkage of HHC10 to the 16-ene 
films was confirmed using DRIFT spectroscopy, by comparing lyophilized HHC10 solid 
powder to HHC10 that had been linked to 5% HA discs (Figure 4.6). 
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Figure 4.6: DRIFT spectra indicating successful immobilization of HHC10. A) Thiol 
stretching before (blue) and after (red) peptide linking, showing the loss of the S-H stretch. 
B) Sulfide bond stretches before (blue) and after (red) peptide immobilization 
corresponding to νC-S cysteine, solid at 702 cm-1 and νC-S cysteine and νC-S acid to peptide at 735, 716, 
673 and 652 cm-1. C) Amide I (νC=O) and amide II (νN-H) bands for solid (blue) and linked 
peptide (red) indicating the presence on the peptide on the 5% HA composite. 
  
 The solid HHC10 contained peaks corresponding to the vS-H at 2661 cm
-1, vC-S at 
702 cm-1 and vamide I and vamide II at 1661 and 1640 cm
-1. In the linked HHC10 spectra, the 
vS-H peak is no longer present and the single vC-S stretch has split into two sets of peaks that 
are shifted to 735, 716, 673 and 652 cm-1. These changes are indicative of successful 
immobilization of HHC10 because the click reaction takes place between the cysteine’s 
side chain thiol and forms a new sulfide bond. The amide I and II region of the DRIFT 
spectrum was also examined. In the linked HHC10 the vamide I was observed at 1660 cm
-1 
A B 
C 
2800 2700 2600 2500
98.5
99.0
99.5
100.0
2661
Blue = Solid Inverso-CysHHC10
Red = Linked Inverso-CysHHC10
Wavenumbers (cm-1)
%
 R
ef
le
ct
an
ce
740 720 700 680 660
96
97
98
99
100
702
652
673
716
735
Blue = Solid Inverso-CysHHC10
Red = Linked Inverso-CysHHC10
 
%
 R
ef
le
ct
an
ce
Wavenumbers (cm-1)
100
99
98
1660 1640 1620 1600
94
96
98
100
%
 R
ef
le
ct
an
ce
Wavenumbers (cm-1)
Blue = Solid Inverso-CysHHC10
Red = Linked Inverso-CysHHC10
1640/1640
1661/1660
 92 
and the vamide II at 1640 cm
-1, matching those observed in the solid HHC10. The changes 
observed in the thiol and sulfide regions, coupled with the persistence of the amide I and 
II, confirm the successful immobilization of HHC10 to the 5% HA composite. 
 
4.3.2 Quantification of Antimicrobial Peptide Immobilization 
on 5% HA 
 The amount of HHC10 that was covalently linked to the 5% HA composites was 
determined using fluorescence. HHC10 modified 5% HA discs were prepared using the 
alkene-thiol linker system described in Section 4.2.3. Ten discs were covalently modified 
and the fluorescence of the reaction solution at 342 nm, due to the four tryptophan residues 
within HHC10, was correlated to the amount of HHC10 that had been linked. 
  By monitoring the fluorescence emission and using the calibration curve (Figure 
4.7), the average amount of AMP immobilized using this alkene-thiol linker system was 
found to be 470 ± 20 μg HHC10 per 5% HA disc. The 5% HA discs used here weigh on 
average 0.053 grams, which translates to an antimicrobial loading of 8850 ± 90 μg HHC10 
per gram of modified 5% HA composite. 
 
 
 
 
 
 
Figure 4.7: Calibration curve used for the quantification of the amount of immobilized 
HHC10 on the 5% HA composites. 
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4.3.3 Quantification of Antimicrobial Peptide Released from 
HHC10 Modified 5% HA 
 The quantity remaining and stability of immobilized HHC10 over time in aqueous 
solution was evaluated using Direct Infusion Q-TOF MS. HHC10 modified 5% HA discs 
were soaked in ddH2O for 1, 3.5 and 24 hours. At each time point the discs were removed 
and the ddH2O was analyzed. The limit of detection of HHC10 in ddH2O using this method 
was found to be 9.9x10-9 M and the limit of quantification was 3.0x10-8 M (Figure 4.8).  
 
 
 
 
 
Figure 4.8: Calibration curve used to quantify the amount of HHC10 released into solution. 
 
 After 1 hour the concentration of HHC10 in the ddH2O was 3.71x10
-7 ± 0.73x10-7 
M, after 3.5 hours the total concentration of HHC10 in solution was 5.01x10-7 ± 0.50x10-7 
M and following 24 hours of soaking the total concentration of HHC10 in solution was 
5.67x10-7 ± 0.20x10-7 M. Using the determined concentrations and the sample volume, the 
corresponding mass of HHC10 in solution was determined. After 1 hour the average mass 
of HHC10 released from the modified 5% HA discs was 1.15 ± 0.23 μg, then after 3.5 
hours the total amount of HHC10 released was 1.55 ± 0.15 μg and after soaking for 24 
hours the total mass of HHC10 released from the composite and into the ddH2O was 1.75 
± 0.06 μg. The amount of HHC10 liberated from the modified 5% HA significantly 
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increased between 1 and 3.5 hours, but the increase was not significant between 3.5 and 24 
hours. The average percentage of HHC10 that remained linked to the 5% HA was 
quantified using the average loading determined in Section 4.3.2. After 24 hours of soaking 
the modified 5% HA discs, the average amount of HHC10 that remained immobilized 
using the developed alkene-thiol linker system was 99.63 ± 0.01% (Figure 4.9). 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: The percentage of Inverso-CysHHC10 that remains linked to 5% HA using 
the alkene-thiol linker system through a 24 hour soak in ddH2O, shown as mean ± standard 
error, p<0.05. 
 
4.3.4 Escherichia coli NPN Uptake Factor on Modified 5% HA 
 A proposed mechanism of AMP action is through cell membrane disruption, where 
the AMPs form trans-membrane pores that result in the collapse of the cell membrane and 
leads to cell death.43,44,47 Changes in E. coli membrane permeability were evaluated using 
the NPN uptake assay. E. coli cultures were grown to 0.5 OD600 nm and treated with HHC10 
modified 5% HA discs. The fluorescence intensity of the samples was collected and the 
NPN uptake factors were determined and normalized to untreated E. coli. The normalized 
NPN uptake factors were: control untreated E. coli: 1.00 ± 0.01 and HHC10 modified 5% 
HA treated E. coli: 1.35 ± 0.02 (Figure 4.10). The normalized NPN uptake factor of the 
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treated E. coli was statistically higher than the NPN uptake factor of untreated E. coli, 
indicative of increased membrane permeability. Which clearly demonstrates that the 
HHC10 retains its activity against E. coli when it is covalently immobilized to a 5% HA 
composite using the developed alkene-thiol linker system. 
 
 
 
 
 
 
Figure 4.10: Normalized NPN uptake factor for untreated E. coli and E. coli treated with 
HHC10 modified 5% HA discs. Data shown as mean ± standard error, p<0.05. E. coli 
treated with modified discs exhibit increased membrane permeability. 
 
4.3.5 Escherichia coli Bacterial Turbidity Tests with Modified 
5% HA 
 The activity of linked HHC10 was further evaluated by monitoring the growth of 
E. coli in planktonic culture when incubated with HHC10 modified 5% HA. After 
incubating a 0.1 OD600 nm E. coli solution for 2.5 hours with modified 5% HA, the OD600 
nm was measured for all samples and normalized to untreated E. coli. The normalized 
average OD600 nm for E. coli solutions were: control untreated E. coli: 1.00 ± 0.02 and 
HHC10 modified 5% HA treated E. coli: 0.24 ± 0.01 (Figure 4.11). Based on the decreased 
OD600 nm, the growth of E. coli incubated with HHC10 modified 5% HA discs was 
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effectively inhibited.  Further demonstrating the immobilized HHC10 retains its activity 
against the E. coli. 
 
 
 
 
 
Figure 4.11: Normalized OD600 nm for untreated E. coli and E. coli treated with HHC10 
modified 5% HA discs. Data shown as mean ± standard error, p<0.05. E. coli treated with 
modified discs exhibit decreased OD600 nm and decreased bacterial growth in culture. 
 
4.3.6 Inverso-CysHHC10 Antimicrobial Activity in Solution 
and Linked to Modified 5% HA  
 Based on the NPN uptake assay and bacterial turbidity test, it was clearly shown 
that the immobilized HHC10 retains its antimicrobial activity against E. coli. The efficacy 
of the linked AMP was further compared to the free, in solution HHC10 to determine the 
concentration dosage that the linked AMP was equally as effective as. 
 E. coli was cultured and treated as described in Section 4.2.8. Using the NPN uptake 
assay, the fluorescence intensity of the samples was collected and the NPN uptake factors 
were determined and normalized to the untreated E. coli. The NPN uptake factors were: 
control untreated E. coli: 1.00 ± 0.01; 10 μM HHC10 treated E. coli: 1.36 ± 0.01 and 
HHC10 modified 5% HA treated E. coli: 1.35 ± 0.02. (Figure 4.12). The NPN uptake 
factors of the treated E. coli, both 10 μM HHC10 and HHC10 modified 5% HA discs, were 
statistically higher than that of untreated E. coli. Further, the NPN uptake factor of linked 
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and 10 μM HHC10 were statistically equivalent, demonstrating that immobilized HHC10 
is as effective as a 10 μM AMP solution. 
 
 
 
 
 
 
 
 
 
Figure 4.12: NPN uptake assay for E. coli treated with 10 μM and linked HHC10, shown 
as mean ± standard error, p<0.05. Both treated E. coli solutions have a statistically higher 
NPN uptake factor than untreated E. coli and are statistically equivalent. 
  
 E. coli was cultured and treated as described in Section 4.2.9. Using the bacterial 
turbidity test, the OD600 nm of E. coli solutions were collected and normalized to the 
untreated bacteria solutions. The normalized OD600 nm for the E. coli solutions were: control 
untreated E. coli: 1.00 ± 0.02; 10 μM HHC10 treated E. coli: 0.25 ± 0.02 and HHC10 
modified 5% HA treated E. coli: 0.24 ± 0.01 (Figure 4.13). The OD600 nm of the E. coli 
incubated with both the 10 μM HHC10 and HHC10 modified 5% HA discs were 
statistically lower than the untreated E. coli. Additionally, the OD600 nm of E. coli treated 
with 10 μM HHC10 and linked HHC10 were statistically equal, confirming the linked 
HHC10 prevents E. coli growth as effectively as a 10 μM HHC10 solution. 
 Based on both the NPN uptake assay and E. coli bacterial turbidity test, the linked 
HHC10 is equally effective against E. coli as a 10 μM HHC10 solution. 
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Figure 4.13: Bacterial turbidity tests for E. coli treated with 10 μM and linked HHC10, 
shown as mean ± standard error, p<0.05. Both treated E. coli solutions have a statistically 
lower OD600 nm than untreated E. coli and are statistically equivalent. 
 
4.3.7 Osteoblast Attachment to Modified 5% HA 
 To evaluate if the immobilization of HHC10 affected the increased osteoblast 
attachment observed on the unmodified 5% HA, NHOsts were cultured and seeded onto 
sterilized, HHC10 modified 5% HA discs. Nine discs were placed into a 48 well plate per 
time point and loaded with 10,000 NHOsts. After 1, 4 and 7 days the cells were imaged 
using the Live/Dead® Viability/Cytotoxicity assay kit. Five images per disc were collected 
(Figure 4.14) and the number of live cells was counted and normalized to the control.  
 
 
 
 
 
 
 
 
Figure 4.14: Representative Live/Dead® fluorescent images of osteoblasts attached to 
control unmodified and HHC10 modified 5%HA composites on Days 1, 4 and 7. 
Day 1 Day 4 Day 7 
Unmodified 
5% HA 
HHC10 
modified 
5% HA 
0.2
0.4
0.6
0.8
1.0
N
o
rm
al
iz
ed
 O
D
6
0
0
 n
m
Untreated 
  E. coli
10 M  
HHC10
Linked 
HHC10
 99 
 On Day 1 the normalized average number of live osteoblasts per view was: control 
unmodified 5% HA: 100.0 ± 7.7 and HHC10 modified 5% HA: 105.5 ± 8.7 (Figure 4.15). 
The HHC10 modified 5% HA composites had statistically the same number of attached 
live cells as unmodified 5% HA on Day 1. 
 On Day 4 the normalized average number of live osteoblast cells per view was: 
control unmodified 5% HA: 100.0 ± 9.4 and HHC10 modified 5% HA: 101.1 ± 9.2 (Figure 
4.15). Again, the HHC10 modified 5% HA discs had the statistically same number of cells 
per view as unmodified 5% HA. 
 The normalized average number of live osteoblast cells per view on Day 7 was: 
control unmodified 5% HA: 100.0 ± 6.1 and HHC10 modified 5% HA: 103.9 ± 4.8 (Figure 
4.15). The amount of attached live cells was once again statistically the same for HHC10 
modified and unmodified 5% HA.  
  
 
 
 
 
 
Figure 4.15: Days 1, 4 and 7 normalized average number of live osteoblasts attached to 
control unmodified and HHC10 modified 5% HA composites. Data represented as mean ± 
standard error, p<0.05. The average number of attached live cells is statistically equal on 
all days examined. 
 
 The number of live osteoblasts attached the HHC10 modified 5% HA was 
statistically equal to the number attached to unmodified 5% HA on all days examined.  
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These results prove that the covalent immobilization of the AMP does not have a negative 
effect on the osteoblasts cultured on the composites.  
 
4.3.8 Osteoblast Viability on Modified 5% HA 
 To examine the effect of immobilizing HHC10 on osteoblast viability, NHOsts 
were cultured and seeded onto sterilized, HHC10 modified 5% HA discs. Nine sterilized 
discs per time point were placed into a 48 well plate and loaded with 10,000 NHOsts. After 
1, 4 and 7 days the cells were imaged using the Live/Dead® Viability/Cytotoxicity assay 
kit. Five images per disc were collected. The number of live cells was divided by the total 
number of cells to determine the percent viability of the NHOsts. 
 On Day 1 the percent cell viability was: control unmodified 5% HA: 84.4 ± 1.8 and 
HHC10 modified 5% HA: 85.6 ± 1.7 (Figure 4.16). The HHC10 modified and unmodified 
5% HA had same percentage of attached viable cells.  
 The percent cell viability on Day 4 was: control unmodified 5% HA: 74.4 ± 2.5 and 
HHC10 modified 5% HA: 78.6 ± 3.0 (Figure 4.16). Again both modified and unmodified 
5% HA had statistically the same percent cell viability. 
 On Day 7 the percent cell viability was: control unmodified 5% HA: 81.6 ± 1.2 and 
HHC10 modified 5% HA: 87.1 ± 1.3 (Figure 4.16). The percentage of viable cells on the 
HHC10 modified 5% HA was statistically higher than that of cells on unmodified 5% HA. 
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Figure 4.16: Days 1, 4 and 7 percent viability of attached cells on control unmodified and 
HHC10 modified 5% HA composites. * = statistically higher than control for that day. Data 
represented as mean ± standard error, p<0.05. The percent viability is equal on Day 1 and 
4 and statistically higher on Day 7. 
 
 The immobilization of HHC10 also does not adversely affect the percent viability 
of the attached osteoblasts. At the longest time point the percent viability was greater on 
the HHC10 modified 5% HA.  
 
4.3.9 Osteoblast Proliferation on Modified 5% HA 
 To determine if the presence of HHC10 had an effect on osteoblast proliferation, 
NHOsts were cultured and seeded onto sterilized, HHC10 modified 5% HA discs. Nine 
discs at each time point were placed into 48 well plates and loaded with 10,000 cells. Before 
evaluating proliferation, the alamarBlue® reagent was diluted into the OBM. After 1, 4 
and 7 days the OBM was examined using UV-VIS spectroscopy. The absorbance of the 
OBM from each well was collected and normalized to control unmodified 5% HA. 
 On Day 1 the normalized average absorbance was: control unmodified 5% HA: 
100.0 ± 2.5 and HHC10 modified 5% HA: 103.2 ± 4.2 (Figure 4.17). The amount of cell 
proliferation supported was statistically equal between modified and unmodified 5% HA. 
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 The normalized average absorbance on Day 4 was: control unmodified 5% HA: 
100.0 ± 1.8 and HHC10 modified 5% HA: 98.1 ± 2.8 (Figure 4.17). Again, cell 
proliferation was equally supported on both the control and HHC10 modified 5% HA discs. 
 By Day 7 the normalized average absorbance was: control unmodified 5% HA: 
100.0 ± 4.6 and HHC10 modified 5% HA: 101.2 ± 4.3 (Figure 4.17). Similar to the previous 
days, the absorbance was statistically equal between control and modified samples.  
 
 
 
 
 
 
Figure 4.17: Days 1, 4 and 7 normalized absorbance of OBM for control unmodified and 
HHC10 modified 5% HA composites. Data represented as mean ± standard error, p<0.05. 
The amount of cell proliferation is statistically equal on all days examined. 
  
 The HHC10 modified 5% HA discs supported cell proliferation equally as well as 
the unmodified 5% HA on all days examined. Again, these results demonstrate that the 
immobilization of HHC10 does not affect the increased cell proliferation observed on the 
5% HA composite. 
 
4.4 Discussion 
 Implant associated infections are difficult to eliminate because of their antibiotic 
resistant characteristics.15,19-21 Frequently, by the time the infection is discovered it is in an 
advanced stage, when the removal of the implant is the best approach for treatment.2,13-
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15,17,27 To avoid this colonization, an antimicrobial molecule that is localized to the graft 
and is present upon implantation is desirable.31-33,36,37 To also avoid the growing concern 
over antibiotic resistance, an immobilized antimicrobial peptide was investigated.41-44 The 
AMP was covalently attached to the composite 5% HA materials through a two-step 
alkene-thiol click reaction. DRIFT spectroscopy confirmed both of the steps of the 
modification proceeded successfully and Q-TOF MS confirmed the quantity and stability 
of the attached HHC10. HHC10 modified 5% HA discs were then sterilized by autoclaving 
and evaluated biologically.  
 Antibacterial efficacy, of both the linked and in solution HHC10, was evaluated 
through the NPN uptake assay and bacterial turbidity tests.36,54-56 A proposed mechanism 
of AMP action is through cell membrane disruption, where the AMPs form trans-
membrane pores that results in the collapse of the cell membrane and cell death.41,44 
Changes in membrane permeability for E. coli treated with HHC10 modified 5% HA and 
10 μM HHC10 were evaluated using the NPN uptake assay. NPN uptake was increased by 
40% for the E. coli treated using both types of HHC10. Further, the uptake was statistically 
equal for both the linked HHC10 and the 10 μM HHC10 (p<0.05), demonstrating that the 
linked AMP permeabilizes the E. coli membrane as well as a 10 μM solution. The LC99.9 
of “free” HHC10 is 8 μM and the effective dosage of the linked HHC10 is 10 μM, showing 
that the linked HHC10 retains its activity against E. coli through linkage.49  
 The prevention of bacterial growth in culture was monitored using the bacterial 
turbidity test.36,56 As bacteria are grown in culture, they create a turbid solution, where the 
greater the concentration of bacteria, the greater the turbidity of that solution. Through this 
assay a similar HHC10 effectiveness was observed to seen in the NPN uptake assay. Both 
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the HHC10 modified 5% HA discs and with 10 μM HHC10 resulted in a 75% decrease in 
E. coli solution turbidity. This decrease was equal for both HHC10 treated E. coli samples. 
This assay confirmed that the linked AMP is equally as effective at preventing the growth 
of E. coli in culture as the 10 μM HHC10 solution.  The bacterial turbidity test coupled 
with the NPN uptake assay verified that the covalent immobilization of HHC10 does not 
render the AMP inactive, but rather the activity is only slightly diminished.  
 Since the goal was to develop a material that increased osteoblast performance and 
simultaneously decreased bacterial attachment, once the HHC10 had been immobilized to 
the 5% HA the material and evaluated for its antibacterial properties, osteoblast 
performance on the HHC10 modified 5% HA materials was re-examined. The presence of 
HA at the composite interface was shown to increase osteoblast response on unmodified 
5% HA discs. When the osteoblast attachment, viability and proliferation were examined 
on HHC10 modified 5% HA, it was shown that the immobilization of HHC10 does not 
affect the bone cell performance. On Day 1 and Day 4, the number of attached cells, percent 
cell viability and cell proliferation were all comparable on HHC10 modified and 
unmodified 5% HA. On Day 7 the number of attached cells and cell proliferation were 
statistically the same and the percent cell viability was increased on HHC10 modified 5% 
HA over control.  
 These osteoblast performance assays consistently demonstrated that the HHC10 
modification did not impede with the osteoblast response. This indicates that despite the 
immobilization of HHC10 onto the 5% HA composites, there is still sufficient surface 
contact area available for cells to interact. If the HHC10 formed a complete layer on the 
CaAlO:HA surface the cells would not be able to interact with the composite and the 
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cellular response would decrease. Previous work had demonstrated that “free” HHC10 
induced hemolysis in only 1% of erythrocytes.49 Although the work here did not explicitly 
quantify the amount of cell death, it was clearly shown that HHC10 immobilization did not 
decrease the number of attached live cells or the percent viability of those cells. 
 Based on the biological evaluation of the HHC10 modified 5% HA composite, the 
multifunctional material had been developed. The 5% HA had an elastic modulus and 
modulus of rupture that was similar to non-load bearing cancellous bone and consistently 
resulted in increased osteoblast attachment, viability and proliferation. Chemical 
functionalization with an antimicrobial peptide added antibacterial properties to the 
material and did not sacrifice the bone cell performance. Based on the mechanical and 
biological evaluation performed on the HHC10 modified 5% HA it was determined that 
this composite is suitable for a synthetic bone graft and has the ability to address multiple 
physiological stresses that would be placed on it. 
 
4.5 Conclusions 
 DRIFT analysis confirmed the RT-formed 5% HA composite was successfully 
functionalized with the potent antimicrobial peptide Inverso-CysHHC10. Immobilization 
was achieved using the highly efficient alkene-thiol click reaction and the HHC10 
remained localized on the 5% HA disc for at least 24 hours. Through covalent 
immobilization the HHC10 retained its bactericidal activity and functioned with the 
potency of a 10 μM HHC10 solution, based on the increased E. coli membrane permeability 
and the reduced growth of E. coli in culture. Most importantly, the linked HHC10 did not 
adversely affect the increased osteoblast response observed on the unmodified 5% HA 
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composites. Cell attachment and proliferation on HHC10 modified and unmodified 5% HA 
was statistically equivalent on all the days examined and percent cell viability was 
increased on the longest time point. These results clearly demonstrate that the increased 
osteoblast response is not affected by the attachment of the antimicrobially active HHC10.   
Further the alkene-thiol linker system utilized here can be extended to other system where 
the material contains reactive surface hydroxyl groups and the antimicrobial molecule 
contains or can be amended to include a sacrificial thiol functionality.  
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Chapter 5: Conclusions 
5.1 Effect of Hydroxyapatite Incorporation into Calcium 
Aluminum Oxide 
 To improve the biocompatibility and osteogenic ability of the CaAlO material, it 
was cast as part of a composite with the osteoinductive and osteoconductive calcium 
phosphate material, HA.1-3 HA was utilized due to its chemical similarity to the mineral 
component of natural bone and its previously demonstrated ability to increase in vivo bone 
regeneration.2,4-6 By pairing small amounts of the osteogenic HA with the mechanically 
strong CaAlO, a new potential bone scaffold material was developed and evaluated. 
 
5.1.1 Phase Composition of Cast Composites 
 The composites were formed using a room temperature cast where three different 
aggregate sizes of CaAlO were mixed with ground Ca3(PO4)2 and hydrated using a dilute 
H3PO4 solution. Composites containing 1-5, 10, 15, 20 and 25% HA were successfully 
formed and evaluated for their phase composition. When CaAlO was exclusively cast, 
three different calcium aluminum phases were found using PXRD, CaAl4O7, CaAl2O4 and 
Ca3Al2(OH)12, and when Ca3(PO4)2 was cast two difference phases were detected 
Ca5(PO4)3OH (HA) and CaHPO4·2H2O. When CaAlO and Ca3(PO4)2 were cast together 
the same five phases were observed, indicating that there are no cross reactions taking place 
and there is no mixing of the two primary materials (CaAlO and Ca3(PO4)2). SEM-EDS 
further confirmed the presence, abundance and distribution of the cast HA at the composite 
interface where in vitro cellular interactions can occur.  
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5.1.2 Mechanical Properties of Cast Composites 
 Two different post hydration processes were examined to determine the effect on 
the mechanical properties of the cast composites. The post hydration methods tested were 
1) drying at room temperature and 2) sintering at 1000°C for 4 hours.  These methods were 
evaluated because CaAlO derives its strength from hydration with water at room 
temperature, whereas HA derives its strength from sintering. The materials were evaluated 
for both the effect of increasing amount of HA in the composite and the effect of post 
hydration processing. The addition of HA to the composite was shown to significantly 
decrease the mechanical strength with larger amounts of HA (>10%), to the point where 
these composites were not similar in strength to natural non-load bearing cancellous bone. 
Post hydration processing also played a significant role in composite strength. All sintered 
composites had statistically lower elastic moduli and >10% HA composites had lower 
moduli of rupture. Ultimately the low percentage HA composites were the closest match 
to structural cancellous bone and were evaluated for ability to increase osteoblast response. 
 
Table 5.1: Mechanical properties of natural bone and the 5% HA developed in this work.  
 
 
 
 
 
 
 
 
 Elastic Modulus (GPa) Modulus of Rupture (MPa) 
Load Bearing          
Cortical Bone 
15-22 60-75 
Non-Load Bearing 
Cancellous Bone 
3-11 4-9 
RT-formed 5% HA 
Composite 
8.8-11 5.7-7.1 
 114 
5.1.3 Osteoblast Response on 1-5% HA 
 The low percentage of HA composites that were mechanically similar to non-load 
bearing cancellous bone were examined for increased osteoblast response. Osteoblast cells 
were cultured and seeded onto sterilized 1-5% HA discs and evaluated for cellular 
attachment, percent viability and proliferation on Days 1, 4 and 7 after seeding. 
Significantly increased osteoblast attachment was observed on all 1-5% HA composites on 
Days 4 and 7. However, on Day 1 only the 5% HA had significantly increased osteoblast 
attachment. Cell viability was significantly increased on all composites on Days 4 and 7, 
and on 1%, 4% and 5% HA on Day 1. Cell proliferation was increased on Days 4 and 7 for 
all composites and on 4% and 5% HA on Day 1. The 5% HA had osteoblast attachment 
and proliferation that was significantly higher than all other composites on the days 
examined. Therefore the 5% HA is the composite that is mechanically the most similar to 
non-load bearing cancellous bone and also increases osteoblast response the most over all 
other composites. 
 
5.2 Inverso-CysHHC10 Antimicrobial Activity: Surface 
Immobilized vs. in Solution 
 After determining that the 5% HA composite was the most suitable material 
mechanically and for increased osteoblast response, the composite was functionalized to 
prevent E. coli growth.7-9 The broad spectrum antimicrobial peptide HHC10 was covalently 
linked to the 5% HA in a two-step alkene-thiol click reaction, where the material serves as 
the delivery vehicle for the antimicrobial, and the 16-ene film serves as the organic spacer 
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group giving the AMP steric freedom at the interface.10,11 Mass spectral analysis revealed 
the stability of the newly formed sulfide bond that kept greater than 99.6% of the HHC10 
localized to the material through 24 hours soaking in water. The activity of the linked 
HHC10 was determined through the NPN uptake factor and bacterial turbidity test. 
Increased bacteria cell membrane permeability was evaluated using the NPN uptake 
assay.12,13 Results indicated increased NPN uptake for E. coli treated with HHC10 modified 
5% HA versus unmodified 5% HA, as a result of AMP activity and membrane pore 
formation. The growth of E. coli in planktonic culture was also significantly reduced as 
indicated by the OD600 nm in the bacterial turbidity test.
14,15 The amount of AMP covalently 
linked to the 5% HA composite was as effective against E. coli as a 10 μM HHC10 solution, 
which is slightly greater than the 8 μM LC99.9 of free Inverso-CysHHC10.10,11 Both of 
these assays confirm that HHC10 retains its antimicrobial activity through the alkene-thiol 
immobilization, resulting in the antimicrobially active 5% HA interface. 
 
5.3 Osteoblast Response on Inverso-CysHHC10 Modified        
5% HA 
 In an ideal multifunctional system, the function of one modification should not be 
affected by the other. Therefore, once the covalent attachment and antimicrobial evaluation 
of HHC10 was completed, the increased osteoblast response observed on unmodified 5% 
HA was re-examined. Osteoblasts were cultured and seeded onto sterilized HHC10 
modified 5% HA and examined for their attachment, viability and proliferation on Days 1, 
4 and 7. Statistically equivalent cellular attachment was observed on HHC10 modified and 
unmodified 5% HA on all days examined. The extent of osteoblast proliferation on the 
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HHC10 modified 5% HA was again statistically equal to the unmodified 5% HA on Days 
1, 4 and 7. Finally percent cell viability was the same on HHC10 modified and unmodified 
5% HA on Days 1 and 4, and was statistically higher on modified 5% HA on Day 7. These 
outcomes demonstrate that the independent functions of the 5% HA composite are not 
compromised when the AMP is immobilized to the material surface. 
 
5.4 Impact and Future Work  
 Through the execution of this project, the CaAlO material was physically and 
chemically improved for applicability as a bone scaffold material. The incorporation of the 
osteogenic HA into the material resulted in increased osteoblast response without the 
implementation of chemical modification. The use of an alkene-thiol click reaction to link 
an antimicrobial peptide to the composite also demonstrates an improved method for the 
addition of antibacterial activity to these bone scaffold materials.11,16 
 Literature has shown that through the chemical immobilization of cell adhesion 
peptides and osteoinductive proteins osteoblast performance can be significantly increased 
on a variety of materials.14,17-20 However, the enhanced osteoblast response observed on 
the unmodified CaAlO based composites that remain mechanically similar to non-load 
bearing bone is the first result of this nature. By increasing bone cell response through this 
materials-based approach the extent of functionalization and introduction of chemicals to 
the materials has been significantly reduced.  
 The covalent immobilization of Inverso-CysHHC10 to the 5% HA composite that 
remains active through sterilization is a significant contribution towards the limitation of 
implant associated infections. The significance of the antimicrobial peptide being localized 
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to the material is that it allows for effective broad spectrum antimicrobial activity that is 
persistent at the location of implantation. Most importantly, by using an AMP instead of 
an antibiotic, this modification approach plays a critical role in limiting the development 
of antibacterial resistance among strains of bacteria in vitro and in vivo.21-24  
 The design of a multifunctional composite material that actively enhances 
osteoblast response and decreases bacterial growth is significant because it represents an 
advancement in the development of biomaterials that are able to address multiple 
physiological strains that may be placed on the material in an in vivo setting. Further, in an 
ideal multifunctional material one function would not be effected by the other, and the 
system developed here demonstrates that these biological functions work in synergy on the 
material. The modified composites designed here cooperatively address the problems 
associated with mechanical and biological bone graft failure. 
 The reaction sequence used to modify the 5% HA interface is further applicable to 
other relevant biomaterial surfaces. Any interface that contains the reactive surface 
hydroxyl and μ-oxo groups can be functionalized with using this alkene-thiol approach. 
Many current metal oxides used in total joint replacements and arterial and venous stents 
contain these groups and their functionality could be improved through antimicrobial 
modification using an alkene-thiol click linker system.  
 In the future, methods to create macroporosity in the materials without 
compromising mechanical strength would be desirable. A potential approach is to integrate 
the fibrous protein collagen into the material, as natural bone is approximately 60% 
hydroxyapatite and 40% collagen by dry mass. Also, composites that are between 5-10% 
HA may be examined mechanically and biologically because the trend observed in this 
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work is that as the HA percentage increases the osteoblast response increases, but the 
mechanical strength decreases. The alkene-thiol linker system could be utilized to link a 
natural AMP. The HHC10 used here is effective in vitro, however it is a synthetic AMP. 
The human immune system is composed of a large variety of natural AMP’s including 
defensins, cathelicidins and histatins that may be more attractive options in human 
biomaterial applications.25-28 
 Ultimately, in vivo studies using a critical sized bone defect are necessary to 
evaluate the ability of the unmodified and HHC10 modified 5% HA to increase new bone 
formation in a physiological setting.6 Further in vitro bacterial testing with additional 
biofilm forming bacteria including S. aureus and S. epidermidis would be beneficial to 
demonstrate that the linked AMP retains its broad spectrum antibacterial activity.21,29-31 
Upon completing these additional in vitro studies, an in vivo implant associated infection 
model would be necessary to fully evaluate the material for its applicability as a synthetic 
bone scaffold. 
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